[COMPANY_001] Institutes for BioMedical Research
BYM338/Bimagrumab
Clinical Trial Protocol CBYM338X2211
A randomized, subject -and investigator -blinded, 
placebo -controlled study to assess the safety , 
pharmacokinetics and efficacy  of intrav enous bimagrumab 
in ov erweight and obese patients w ith ty pe 2 diabetes
Document type: Amended Protocol Version
EUDRACT number: 2016 -004124 -26
Version number: v05 (Clean ) Incorporating amendment 05
Clinical Trial Phase: II
Release date: 17-Jan-2019
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
[COMPANY_001] Confidential Page 2
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct. Note: The SOM will not be part of the Clinical Study  Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to [COMPANY_001] as 
summarized below.  Refer to Section 9.2 of the protocol for SAE criteria and additional 
requirements.  See also page 2 of the Site Operations Manual for further details on the method 
of reporting a SAE.
Complete SAE report
Submit SAE report to [COMPANY_001] Chief Medical Office and Patient Safet y (CMO & PS)
within 24 hours after awareness of the SAE
Notify  the [COMPANY_001] Medical Lead
The fax number(s) and email address(es) are located in the Site Operations Manual.
[COMPANY_001] Confidential Page 3
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Table of contents
Site Operations Manual (SOM)........................................................................................... [ADDRESS_1011355] of abbreviations ............................................................................................................ 8
Pharmacokinetic definitions and sy mbols ......................................................................... 12
Glossary  of terms ............................................................................................................... 13
Protocol sy nopsis ............................................................................................................... 30
1Introduction ....................................................................................................................... 34
1.1 Background ............................................................................................................ 34
1.1.1 Relevant data summary ......................................................................... 35
1.2 Nonclinical data ..................................................................................................... 35
1.3 Clinical data ........................................................................................................... 36
1.3.1 Human safet y and tolerability  data ....................................................... 36
1.3.2
Human pharmacokinetic data................................................................ 36
1.3.3 Human pharmacod ynamic data ............................................................. 37
1.4 Study  purpose ........................................................................................................ 37
2Study  objectives and endpoints ......................................................................................... 37
2.1 Primary  objective ................................................................................................... 37
2.2 Secondary  objectives ............................................................................................. 37
2.3 Exploratory  objectives ........................................................................................... 38
3Investigational plan ........................................................................................................... 39
3.1 Study  design ........................................................................................................... 39
3.2 Rationale for stud y design ..................................................................................... 41
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....42
3.4 Rationale for choice of comparator ....................................................................... 43
3.5 Rationale for choice of background therapy .......................................................... 44
3.6 Purpose and timing of interim anal yses/design adaptations ................................ ..44
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 4
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
3.[ADDRESS_1011356] to follow -
up ................................................................................................... 64
7.5 Study  Stoppi[INVESTIGATOR_004] .............................................................................................. 64
7.6 Early study termination by [CONTACT_456] ................................ ................................ .65
8 Procedures and assessments .............................................................................................. 65
[COMPANY_001] Confidential Page 5
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.[ADDRESS_1011357] demographics/other baseline characteristics............................................. [ADDRESS_1011358] and Drug Screen .............................................................. 73
8.4.2 Hepatitis and HIV Screen ...................................................................... 73
8.4.3
Testosterone and TSH........................................................................... 73
8.5 Efficacy  / Pharmacod ynamics ............................................................................... [ADDRESS_1011359]....................................................................................... 77
8.6.4 ECG evaluation ..................................................................................... 77
8.6.5 Hematology ........................................................................................... 78
8.6.6
Blood chemistry .................................................................................... 78
8.6.7 Urinal ysis.............................................................................................. 78
8.7 Pharmacokinetics (PK) .......................................................................................... [ADDRESS_1011360] .................................................................................. 79
8.8.2 24 hour dietary  recall assessment .......................................................... 79
8.8.3 Immunogenicity .................................................................................... 79
8.9 Use of residual biological samples ........................................................................ 80
9Safet y monitoring ................................ ................................ ................................ .............. 81
9.1 Adverse events ....................................................................................................... 81
9.2 Serious adverse event reporting ............................................................................. 82
9.2.1 Definition of SAE ................................................................................. 82
9.2.2 SAE reporting
........................................................................................ 83
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 6
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
9.3 Liver safety  monitoring ................................ ................................ ......................... 84
9.4 Lipase and am ylase elevations ............................................................................... 86
9.5 Renal safet y monitoring ......................................................................................... 86
9.6
Reporting medication errors including misuse/abuse............................................ [ADDRESS_1011361] demographics and other baseline characteristics...................................... 91
11.3 Treatments ............................................................................................................. 91
11.4 Analy sis of the primary  variable(s) ....................................................................... 91
11.4.1 Variable(s) ............................................................................................. 91
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 92
11.4.3
Handling of missing values/c ensoring/discontinuations ....................... 92
11.4.4 Sensitivity  anal yses............................................................................... 92
11.5 Anal ysis of secondary  variable(s) .......................................................................... 93
11.5.2 Safet y
..................................................................................................... 93
11.5.3 Pharmacokinetics .................................................................................. 94
11.5.4 Pharmacokinetic / pharmacod ynamic interactions ................................ 94
11.5.5 Other assessments ................................................................................. 94
11.6 Analy sis of exploratory  variables
.......................................................................... 94
11.7
Sample size calculation.......................................................................................... 95
11.8 Power for anal ysis of key secondary  variables ...................................................... 95
11.9 Interim anal yses..................................................................................................... 95
12
Ethical considerations........................................................................................................ 96
12.1 Regulatory
 and ethical compliance ........................................................................ 96
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 96
12.3 Publication of study  protocol and results ............................................................... 97
13Protocol adherence ................................ ................................ ................................ ............ 97
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 7
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
13.1 Protocol Amendments ................................ ................................ ........................... 97
14References ......................................................................................................................... 98
15Appendix 1: L iver Event Definitions and Follow -up Requirements ............................... 100
16
Appendix 2: Specific Renal Alert Criteria and Actions ................................ .................. [ADDRESS_1011362] of tables
Table 3-1 Skin reactions considered possibly  related to bimagrumab from 
unblin ded data* ..................................................................................... 45
Table 3
-2 Muscle sy mptoms considered possibl y related to bimagrumab from 
unblinded data* ................................ ................................ ..................... [ADDRESS_1011363] .................................................................. 71
Table 8
-3 24-hour dietary  recall ................................ ................................ ............ 71
Table 9-1 Safet y monitoring guidance for am ylase and lipase elevations ............ 86
Table 9-2 Summary  of reporting requirements for medication errors................... 87
Table 11-1 Operating characteristics for primary  efficacy  criterion based on 
DXA fat mass (placebo -corrected decrease statistically  significant 
(1-sided p<0.1) and clinically  relevant (estimated median 5 percent 
or more) ................................................................................................. [ADDRESS_1011364] of figures
Figure 3 -
1 Study  design .......................................................................................... 41
[COMPANY_001] Confidential Page 8
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
List of abbreviations
γGT Gamma -glutam yl transferase
ADA American Diabetes Association
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
bid twice dail y
BMI Body Mass Index
BUN blood urea nitrogen
CFR Code of Federal Regulations
CK creatinine kinase
CL Clearance
CMR cardiac magnetic resonance imaging
COPD chronic obstructive pulmonary  disease
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CT computerized tomography
CV coefficient of variation
D5W Dextrose 5% solution
DMC Data Monitoring Committee
DPP4 Dipeptidy l peptidase -4 inhibitor
DXA Dual energy  X-ray absorptiometry
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
ELISA Enzy me-linked immunosorbent assay
EoS End of study
EoT End of treatment
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 9
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
FBM fat body  mass
FDA Food and Drug Administration
FPG Fasting plasma glucose
FSH Follicle -Stimulating Hormone
GCP Good Clinical Practice
h hour
HbA1c glycated haemoglobin test
hCG Human chorionic gonadotropin
HIV human immunodeficiency virus
HOMA2 -IR Homeostatic model assessment 2 – insulin resistance
i.v. intravenous
IA Interim anal ysis
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IRB Institutional Review Board
IUD Intrauterine device
IUS Intrauterine sy stem
kg kilogram(s)
LBM lean bod y mass
LDH lactate deh ydrogenase
LFT Liver function test
Company Confidential Information
Company Confidential Information
Company Confidential Information
Company Confidential Information
Company Confidential Information
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 10
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
MAR Missing at random
MedDRA Medical dictionary  for regulatory  activities
mg milligram(s)
mL milliliter(s)
MRI Magnetic resonance imaging
MTT Meal Tolerance Test
NCDS [COMPANY_001] Clinical Data Standards
NOAEL no-observed - adverse- effect -level
PD pharmacod ynamic(s)
PG pharmacogenetics(s)
PK pharmacokinetic(s)
PoC Proof of Concept
PRO Patient reported outcome
QTcF Fridericia QT correction formula
QUICKI quantitative insulin -sensitivity  check index
RNA ribonucleic acid
s.c. subcutaneous
SAE serious adverse event
sCR serum creatinine
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic p yruvic transaminase
sIBM sporadic inclusion body  myositis
S Source data
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 11
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
SOM Site Operations Manual
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
T2D Type [ADDRESS_1011365] upper limit of normal
US ultrasound
WHO World Health Organization
WOC Withdrawal of Consent
Company Confidential Information
[COMPANY_001] Confidential Page 12
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Pharmacokinetic definitions and sy mbols
CmaxThe observed maximum plasma (or serum or blood) concentration following 
drug administration [mass / volume]
CtroughThe trough observed analy te concentration is the concentration that is just 
prior to the beginning of, or at the end, of a dosing interval
Tmax The time to reach the maximum concentration after drug administration [time]
[COMPANY_001] Confidential Page 13
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Glossary  of terms
Assessment A procedure used to generate data required b y the study
Cohort A specific group of subjects fulfilling certain criteria
Control drugAny drug (an active drug or an inactive drug, such as a placebo) which 
is used as a comparator to the investigational drug being tested in the 
trial
DosageDose of the study  treatment given to the subject in a time unit 
(e.g. 100mg once a day , 75 mg twice a day )
EnrollmentPoint/time of subject entry  into the study  at which informed consent 
must be obtained (i.e. prior to starting any of theprocedures described 
in the protocol)
EpochInterval of time in the planned conduct of a study . An epoch is 
associated with a purpose (e.g. screening, randomization, treatment, 
follow -up), which app lies across all arms of a study
Health y volunteerA person with no known significant health problems who volunteers to 
be a stud y participant 
Investigational drugThe study  drug whose properties are being tested in the study ; this 
definition is consistent with US CFR 21 Section 312.3 and Directive 
2001/20/EC and is synony mous with “investigational new drug” or 
“test substance”
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the 
study  as well as their associated treatment controls. This includes any 
placebos, any active controls, as well as approved drugs used outside 
of their indication/approved dosage or tested in a fixed combination. 
Investigational treatment generall y does not include other treatments 
administered as concomitant background therapy required or allowed 
by [CONTACT_740128]/dosage
PartA single component of a study  which contains different objectives or 
populations within that single study . Common parts within a study  are: 
a single dose part and a multiple dose part, or a part in patients with 
established disease and in tho se with newly -diagnosed disease
Patient An individual with the condition of interest
PeriodA minor subdivision of the study  timeline; divides phases into smaller 
functional segments such as scre ening, baseline, titration, washout, etc.
Personal DataSubject information collected b y the Investigator that is transferred to 
[COMPANY_001] for the purpose of the clinical trial. This data includes subject 
identifier information, study  information and biological samples.
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the planned 
completion of all study  drug administration and assessments; at this 
time all study  drug administration is discontinued and no further 
[COMPANY_001] Confidential Page 14
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
assessments are planned
Randomization 
numberA unique identifier assigned to each randomized subject, 
corresponding to a specific treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
Study  completionPoint/ti me at which the subject came in for a final evaluation visit or 
when study  drug was discontinued whichever is later
Study  drug 
discontinuationPoint/time when subject permanentl y stops taking study  drug for any 
reason; may or may not also be the point/tim e of premature subject 
withdrawal
Study  
drug/treatmentAny drug (or combination of drugs) administered to the subject as part 
of the required study  procedures; includes investigational drug, active 
drug run -ins or background therapy .
Study  treatmentAny drug administered to the study  participants as part of the required 
study  procedures; includes investigational drug (s), control(s) or non-
investigational medicinal product(s)
Study  treatment 
discontinuationWhen the subject permanently  stops taking study treatment prior to the 
defined stud y treatment completion date
Subject A trial participant (can be a healthy  volunteer or a patient)
Subject numberA unique number assigned to each subject upon signing the informed 
consent. This number is the definitive , unique identifier for the subject 
and should be used to identify  the subject throughout the study  for all 
data collected, sample labels, etc
VariableA measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  occurs only when a subject does 
not want to participate in the study  any longer, and does not allow an y 
further collection of personal data
[COMPANY_001] Confidential Page 15
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 16
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 17
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Info rmation
[COMPANY_001] Confidential Page 18
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Info rmation
[COMPANY_001] Confidential Page 19
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Info rmation
[COMPANY_001] Confidential Page 20
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 22
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 23
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 25
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 26
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Com pany Confidential Information
[COMPANY_001] Confidential Page 27
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Info rmation
[COMPANY_001] Confidential Page 28
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 29
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Company Confidential Information
[COMPANY_001] Confidential Page 30
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Protocol sy nopsis
Protocol number CBYM338X2211
Title A randomized, subject -and investigator -blinded, placebo -controlled study  
to assess the safety , pharmacokinetics and efficacy of intravenous 
bimagrum ab in overweight and obese patients with type 2 diabetes
Brief title Safety, pharmacokinetics and efficacy  study of bimagrum ab in overweight 
and obese patients with type 2 diabetes
Sponsor and Clinical 
Trial Phase[COMPANY_001]
Phase II
Intervention type Drug, Diet, and Moderate exercise 
Study type Interventional 
Purpose and 
rationaleThe main purpose of this study  is to evaluate the efficacy of bimagrumab 
to decrease total body  fat and improve glycemic control by [CONTACT_740129] g 
insulin sensitivity in overweight and obese subjects with type 2 diabetes. 
This study will enable decision making for the development of bimagrumab 
in overweight and obesity and/or metabolic indications.
Primary Objective(s) To evaluate the treatment effect of bimagrumab on tot al body fat mass .
Secondary 
ObjectivesTo evaluate the treatment effect of bimagrumab on total body  fat mass 
after [ADDRESS_1011366] of bimagrum ab on anthropometric body 
measurements and on lean body mass .
Exploratory 
Objectives
Company Confidential Information
[COMPANY_001] Confidential Page 31
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Study design This is a randomiz ed, subject and investigator blinded, placebo -controlled, 
parallel arms study , investigating a 48-week treatment period with 
intravenous bimagrumab in overweight and obese subjects with type 2 
diabetes. Approximately 68subjects are planned to be enrolled and 
randomized. 
Eligible subjects
will be randomized in a 1:1 ratio to bimagrumab or placebo.
Population Approximately 68overweight and obese subjects (BMI: 28-40kg/m2
inclusive) with type 2 diabetes
Males and females between the ages of 18 -75yearsinclusive
Key Inclusion criteria Male and female, age 18 to 75 years (inclusive), in stable health
condition as determined by  [CONTACT_181938], phy sical examination,
vital signs, electrocardiogram, and laboratory tests at screening .
Type 2 diabetes, with an HbA1c between 6.5% and 10% (inclusive) at
screening
On any one of the following anti-diabetes regimens with stable
treatment for approximately 3 months prior to randomization:
1)metform in monotherapy; 2) DPP4 inhibitor agent monotherapy;
3)combination therapy of metformin and DPP4 inhibitor agent;
4) no anti-diabetes therapy.
Body mass index (BMI) of 28 .0to 40 .0kg/m 2(inclusive) at screening.
Body weight between 65 and 140 kg (inclusive) at screening, and with
a stable body  weight (±5 kg) by [CONTACT_969] (patient report) and stable
physical activity within 3 months prior to screening.
Key Exclusion 
criteriaPregnant or nursing (lactating) wom en, where pregnancy is defined as
the state of a female after conception and until the termination of
gestation confirmed by a positive hCG laboratory test.
Women of child- bearing potential, defined as all women physiologically
capable of becoming pregnant, unless they are using highly effective
methods of contraception during dosing and for6 months after
stoppi[INVESTIGATOR_221954].
Diabetes other than type 2 such as type 1 diabetes, surgically
induced -diabetes; "brittle" type 2 diabetes as per investigator
judgment, history of severe hypogly cemic epi[INVESTIGATOR_740111], or hypoglycemic unawareness.
Study treatment Bimagrumab (BYM338)
Placebo
Company Confidential Information
Company Confidential InformationCompany Confidential Information
[COMPANY_001] Confidential Page 32
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Efficacy/PD 
assessmentsDXA scan for whole body ,trunk, appendicular fat and lean mass
HbA1c , HOMA 2-IR,QUICKI and Matsuda Index for glycemic response
Anthropometric measurement of fat by [CONTACT_8497], body  mass index ( BMI),
waist circumference; hip circumference ; waist to hip ratio
Key safety 
assessmentsAdverse events
Physical exam
Vital signs
Laboratory evaluations
ECG
Urinalysis
Other assessments PK samples
IG (immunogenicity)
Dietary intake –including but not limited to total calories, protein, fat,
carbohydrate .
Data analysis The primary aim of the study is to assess the effect of bimagrum ab on 
body  fat mass at Week 48of the treatment period compared to baseline.
The study design enables evaluation of efficacy  based on the following 
dual criteria :1) statistical significance (superior treatment effect, 1-sided 
10% level) in fat mass; and2) clinical relevance of the change in fat mass 
(median treatment effect of at least 5%). Weight loss of 5% has been 
shown to translate into clinical benefit in an overweight and obese 
population with T2D. Fat mass loss of a similar magnitude to 5% weight 
loss is expected to translate into similar clinical benefits, (such as on 
glycemic control )in a similar population.
The randomization will be stratified by [CONTACT_740130] y (>=28 .0kg/m2and 
<=33 .0kg/m2, or >33.1kg/m2 to <=40 .0kg/m2) in order to achieve an 
approximate balance of BMI distribution across the two treatment groups. 
The cutoff value of 33 kg/m2represents the expected median BMI in the 
population based on internal data; therefore ,the two randomization strata 
are expected to be of similar size. However, equal size strata will not be 
enforced. A minimum of [ADDRESS_1011367] in 
both strata (see Section 11.7 ).
A longitudin al model describing fat mass over time will be used, using all 
of the data collected from both randomization strata and adjusting for 
baseline fat mass, treatment arm, baseline BMI.Variables indicating time
and timeby [CONTACT_740131]. An unstructured within -
subject covariance will be used. Thechange in fat mass at Week [ADDRESS_1011368] 5% fat loss at Week 24will be presented by [CONTACT_740132] 33
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
group.
Key wo rds Bimagrumab, type 2 diabetes, obesity, m yostatin, MRI, DXA
[COMPANY_001] Confidential Page 34
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
[ADDRESS_1011369] yle choices, obesity  is now viewed as a disease 
that is complex, multifactorial, chronic and resistant to many  forms of treatment 
(Mechanick et al 2016). Obesity  is a risk factor for increased overall mortality  and is 
estimated to have caused 3.4 million deaths 
worldwide in 2010 ( Limet al2012). 
Many co-morbidities are associated with obesity, such as type 2 diabetes, hypertension, 
dyslipi[INVESTIGATOR_740112] (Apovian et
al2015). A body  weight reduction of 
5-10% has been associated with sig nificant and clinically  meaningful improvements in insulin
sensitivity , glycemic control, hypertension and dyslipi[INVESTIGATOR_035] (Goldstein 1992; Vidal2002;
Van Gaal eta
l 2005).
There are no approved obesity  interventions that preserve or build lean mass while promoting 
fat mass loss.
The activin type 2 receptors (ActRIIA and ActRIIB, collectivel y abbreviated as ActRII) 
modulate signals for li
gands belonging to the transforming growth factor beta (TGF -β) 
superfamil y such as myostatin, GDF -11, and activin.  Myostatin, activin A, and GDF -[ADDRESS_1011370]  to inhibit muscle protein synthesis and myocyte differentiation and proliferation. 
Blockade of these ligands' action through blockade of ActRII is known to increase skeletal 
muscle mass, which in turn is hypothesized to improve peripheral insulin sensitivity , 
sinceskeletal muscle is one of the major glucose utilizing tissue sin the body . Inhibition of 
ActRII with an antibody has been shown to reduce white adipose tissue in mice on a normal 
or high-fat diet, while increasing skeletal muscle mass, potentially  by [CONTACT_48937] a functional 
increase in brown fat ( Fournier et al 2012 ).
Bimagrumab (BYM338), a recombinant human, monoclonal antibody ,binds competitively  to 
ActRII with greater affinity  than its natural ligands. Bimagrumab is in development for 
muscle wasting indications and has resulted in a significant increase in skeletal muscle mass 
in healthy  volunteers, in patients with sporadic inclusion body  myositis (sIBM), and in 
patients with sarcopenia. Bimagrumab single dose resulted in a profound impact on body 
composition with a maximal reduction in fat mass of ~ 8% and an increase in lean mass of 
~3% (DXA), in overweight and obese pre-
diabetic patients. The net effect on total body  
weight was neutral. Insulin sensitivity  was improved by ~ 18% as measured with a two-step 
hyperinsulinemic eugly cemic clamp. This effect was associated with an absolute reduction in 
HbA1c of 0.2%, an effect size which has been associated with prevention of progression to 
diabetes in a similar population ( DeFronzo et
al2011, Knowler et al2002 ). 
The current study  is designed in overweight and obese individuals with type [ADDRESS_1011371] of adiponectin, levels of which might increase in response to the 
enhanced muscle growth resulting from ActRIIB blockade ( Suzuki et al 2008), on liver fat 
[COMPANY_001] Confidential Page 35
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
and abdominal fat contents (through an hepatic insulin -sensitizing effect, enhanced fat 
oxidation and reduced lipid sy nthesis) will be studied.
1.1.1 Relevant data summary
1.2 Nonclinical data
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 36
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
1.3 Clinical data
1.3.1 Human safety  and tolerability  data
1.3.2 Human pharmacokinetic data
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 37
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
1.3.3 Human pharmacody namic data
1.4 Stud y purpose
The purpose of this study  is to enable decision making for the development of bimagrumab in 
overweight/ obesit y and metabolic indications.
2 Study  objectives and endpoints
2.1 Primary  objective
Primary objective Endpoints related to primary objective
To evaluate the treatment effect of
bimagrumab on total body fat massBody fat mass by [CONTACT_683066] 48
2.2 Secondary  objectives
Secondary objectives Endpoints related to secondary objectives
To evaluate the treatment effect of
bimagrumab on total body fat mass
after 6 months of treatmentBody fat mass by [CONTACT_683066] 24
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 38
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Secondary objectives Endpoints related to secondary objectives
To evaluate the treatment effect of
bimagrumab on gly cemic control and
parameters of insulin sensitivity .HbA1c, fasting glucose and insulin,
HOMA2- IR, QU ICKI, Matsuda index based
on M TTat Week 24 and Week 48.
To evaluate the safety  and tolerability
of bimagrumab in overweight and
obese subjects with t ype 2 diabetes.Adverse events, Vital Signs, ECG,
Laboratory  Values, Immunogenicity .
To evaluate the pharmacokinetics of
repeat doses of bimagrumab in
overweight and obese subjects with
type 2 diabetes.PK samples –pre (Ctrough) and post dose
during treatment and follow- up periods.
Tmax and Cmax ( Day 1, Day 168 and Day
308) will be derived.
To evaluate the immunogenic response
to repeat dosing of bimagrumab in
overweight and obese subjects with
type 2 diabetes.Anti bimagrumab antibodies pre-dose,
during treatment and at the end of stud y.
To evaluate the treatment effect of
bimagrumab on anthropometric bod y
measurements and on lean body  mass .Body weight, BMI, waist circumference,
waist -to-hip rat io, lean body  mass (LBM)
by [CONTACT_683066] 24 and at Week 48.
2.3 Exploratory  objectives
Company Confidential Information
[COMPANY_001] Confidential Page 39
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
[ADDRESS_1011372] and investigator blinded, placebo -controlled, 
parallel arm study , investigating a 48-week treatment period with i.v. bimagrumab 10 mg/kg 
in overweight and obese subjects with ty pe 2 diabetes. Approximately  68subjects are planned 
to be enrolled and randomized
Screening (Day s -21 to -8)
Potential subjects will undergo an onsite screening visit to determine their eligibility  for the 
study  (see enrollment criteria Section 4). Subjects who qualify  for enrollment following 
screening will be scheduled for baseline assessments.
The investigator must recommend 
alifest yle intervention (U.S. Department of Health and 
Human Services Food and Drug Administration Center for Drug Evaluation and Research 
2008) that include sdietary  counseling for weight loss with a daily caloric deficit of 
approximately  500 kcal, with a diet that follows the American Diabetes Association (ADA) 
guidance for optimal glycemic control, and with protein intake of at least 1.2 g/kg/day  to 
support muscle anabolism.  
Subjects must be encouraged to follow a dietcontaining approximately  45
-50% of calories as 
carboh ydrate, 20-25% protein, and 30% fat.Subjects will receive counseling for physical 
activity  and will be encouraged to follow the ADA walking program guidelines (please refer 
to the SOM). These intervent ions will be initiated at screening after eligibility  is confirmed.
Baseline (Day s -7 to -1)
Prior to dosing (Day  1), subjects who are eligible for enrollment following screening will 
return to the clinic to undergo baseline assessments as defined in Section 8.1
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 40
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
(Assessment schedule) . To facilitate study  conduct, subjects may opt to be domiciled on 
Day -1 to complete baseline assessments prior to dosing on Day 1.Subjects will receive a
mobility  tracker device to monitor their phy sical activity .
Randomization and Dosing (Day  1)
Eligible subjects , based on screening and baseline assessments ,will be randomized in a 1:1 
ratio to receive either bimagrumab or placebo. Randomization will be stratified according to 
baseline BM I into 2 strata:
BMI between 28 .0kg/m2and 3 3.0kg/m2(inclusive) and
BMI above 33
.1kg/m2 and up to 40 .0kg/m2 (inclusive).
Administration of bimagrumab or placebo will be done via an intravenous infusion over 
30minutes, followed by [CONTACT_3450]  15 minutes for flushing and then an observation 
period that will include safet y and tolerability  and PK sampling. Following all assessments, 
subjects may be discharged from the Investigator site when the Investigator judges them to be 
medically  stable, in good general health and not needing further observation.
Treatment period ( Days 1 -336)
Subjects should continue on anti-diabetes background therapy  as per eligibility  criteria 
(seeSection 4.1) throughout the study .If,however ,during the course of the study , a subject 
experiences an improvement or a deterioration of his/h er glycemic control, modification of 
his/her background therapy  can be made as defined in Section
6.4(Background therap y dose 
adjustments).
Administration of bimagrumab or placebo will be done via an intravenous infusion over 30minutes 
followed by 10 to 20 minute observation period once every  4 weeks for a total of twelve doses . 
Bimagrumab will be dosed based on body  weight at 10 mg/kg, with a dose cap of 1200 mg for 
body  weight equal to and above 120kg. Placebo will be provided by [CONTACT_740133] 5%Dextrose 
solution (D5W) (see Pharmacy  Manual for more details) .
Subjects will receive regular monitoring and advice on diet and physical activity  as part of 
their month lysite visits (please refer toSection 
8.1(Assessment schedule) )throughout the 
study , and will be contact[CONTACT_5143] , or scheduled for an in-person assessment, once 
between each monthly  sitevisit to provide a 24-hour dietary  recall .Additional methods fo
r 
promoting weight loss may be incorporated into or used in place of standard clinical care; 
these methods may include the use of electronic tools for reporting dietary  intake, weight or 
physical activity , and for receiving feedback on weight trends and lifest yle changes.
Subjects will be asked to return to the Investigator site for dosin g approximately  every 
4weeks during the treatment period. During these visits, subjects will be evaluated for safety, 
tolerability , PK and efficacy . The specific assessments for each of these visits are detailed in 
Section 8.1 (Assessment schedule) .
The treatment per iod will end approximately  [ADDRESS_1011373] dose administration.
[COMPANY_001] Confidential Page 41
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Follow  Up (Day s 364 -392)
After completion of the treatment period, subjects will have a follow -up period of 8 weeks 
with regular monitoring for safet y and efficacy beginning at Week 48 and continuing until the 
end of study  visit (EOS) which will take place [ADDRESS_1011374] study  drug 
administration. Thespecific assessments for the follow up and end of study  visits are detailed 
inSection 8.1 (Assessment schedule) .
Figure 3
-1 Study  design
3.2 Rationale for stud y design
The rationale for key  elements of the study  design include:
Randomization : To decrease the chance of an imbalance in subject characteristics
(e.g., age, BMI) between treatment groups.
Stratification: BMI was selected as a stratification parameter as it is an important
predictor of response for parameters of body composition/body  weight and HbA1c
(internal data). The expected median value for BMI  in this subject population is 33 kg/m2 
(internal data), therefore 2 strata above and below/inclusive of the median will ensure a
balanced representation of subjects between placebo and active drug in each strata, i.e.
strata of approximately  similar size between the 2 arms.
Subject -and investigator -blinding : To mitigate the risk of bias in treatment allocation,
reporting and causality  assessment of adverse events. Furthermore, this design decreases
the potential confounding effect of intentional or unintentional behavioral changes made
by [CONTACT_740134] 42
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Placebo arm: Inclusion of a placebo group will allow the analy sis of whether or not
bimagrumab treatment is more effective than astandard treatment approach based on
lifesty le intervention.
Lifestyle interventions: Trials with anti-obesit y agents have to demonstrate treatment
benefits on body  weight/composition on a background of first line-therapy with lifesty le
interventions. The daily caloric deficit of 500 Kcal with approximately  45-50% calories
from carboh ydrate, 20-25% from protein and 30% from fatis a standard approach and is
expected to induce weight loss over the treatment per iod. It may  also enhance the effect of
bimagrumab on body  composition and body  weight. The American Diabetes Association
(ADA) walking program is tailored to the type of population in this study  and is a gentle,
easy to implement approach for phy sical activity.
 Electronic methods to support participants in making behavioral 
changes to promote weight loss may  also be utilized.
Adequate protein intake: Protein 
content of 1.2 g/kg/day  is recommended toensure
adequate dietary  intake during the period of muscle growth .
Standard of care diabetes therapy: Subjects will remain on their standard of care
treatment for diabetes, enabling the evaluation of added treatment benefit with
bimagrumab on glycemic parameters. Anti- diabetes therap y is restricted to metformin
and/or DPP4 inhibitors, as these medications are less likely  to affect body  weight and thus
confound the stud y results.
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
Dose rationale
In healthy  volunteers (HV) and sIBM patients, a 10 mg/kg d ose of bimagrumab was shown to 
provide exposure levels (i.e. above 10 µg/mL) at which the anabolic effect is observed and 
maintained over dosing intervals of 4 weeks [CBYM338X2102 (N=6 subjects), 
CBYM338X2104 (N=47 subjects)], for up to six doses [CBYM338X2109 (N=35 subjects)] 
. The threshold for minimal 
target exposure for bimagrumab is approximately  10 µg/mL, a concentration below which 
nonlinear clearance is observed, suggesting loss of full receptor saturation and target -mediated 
drug disposition. In clinical studies to date, bimagrumab concentrations approximately  at or 
above 10 µg/mL for at least [ADDRESS_1011375] demonstrated an increase in thigh muscle volume. 
The26-week toxicology studies in cynomolgus monkey s showed achronic exposure at 
NOAEL (300 mg/kg/week) of approximately  300-fold and 55-fold for AUC and Cmax ,
respectivel y,when compared to human exposure s at 10 mg/kg at stead y state.
Dosing in this study  is weight -based for subjects with body  weight up to 120 kg, and is 
capped at 1200 mg for subjects with body  weight between 120 kg and 140 kg. 
Company Confidential Information
Company Confidential Infor mation
[COMPANY_001] Confidential Page 43
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Body-weight based dosing has proven to reduce variability  in exposure in subjects/patients, 
and will be implemented as applicable. Capped dose is selected for body  weights > [ADDRESS_1011376] of large body  weight and body  composition (% fat 
mass vs. % lean mass) on the exposure and safety  profile of bimagrumab. 
To date, the pharmacokinetic data is limited in obese subjects, and the maximal body  weight 
in dosed subjects has been 116 kg, in studies conducted with bimagrumab in overweight to 
obese subjects with insulin resistance (N=10), and obese healthy  subjects (N=6). 
The maximal amount of bimagrumab administered to -date is 3500 mg (at a dose of 30 mg/kg), 
given i.v. and as a single dose for a maximal body weight of 116 
kg. T his dose did not show 
over-exposure and caused no safet y concerns. 
A capped dose for these subjects is selected to avoid over-exposure and to maintain 
bimagrumab levels around the threshold for safe anabolic effects over 4- week dosing intervals. 
Specifica lly, the selected amount of 1200 mg translates to a body  weight based dose ranging 
from 10 to 8.6 mg/kg for the body  weight range of 120-[ADDRESS_1011377] is typi[INVESTIGATOR_740113], the loss of fat mass does not seem to plateau over a 
period of 24 weeks and even up to 64 weeks (Internal data).
Rationale for follow- up period
An off-drug follow -up period is included to monitor the durability  of treatment effect of 
bimagrumab on body  fat mass, lean mass and glycemic control once off treatment. TheEOS 
visit being performed [ADDRESS_1011378] (approximately  8 weeks).
3.4 Rationale for choice of comparator
A placebo will be used as a comparator in this study  based on the following rationale:
A placebo comparator is needed to assess bimagrumab efficacy  over the standard
treatment approach based on lifesty le intervention. Also a placebo comparator does allow
maintain ingthe double blind design.
[COMPANY_001] Confidential Page 44
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
3.[ADDRESS_1011379] line therapeutic agen t, and/orDPP4 
inhibitors. Management of background therapy , including the potential need for managing 
worsening gly cemic control, is presented in Section 6.4 .
3.6 Purpose and timing of interim analy ses/design adaptations
3.[ADDRESS_1011380] of bimagrumab on 
body  weight was neutral, in the presence of a nega tive energy  balance and with a longer 
treatment period, bimagrumab may also induce body  weight loss.  All subjects enrolled in the 
study  maybenefit from the lifesty le interventions including diet and physical activit y, and 
regular monthl y visits.
The risk to patients in this trial will be minimized by  [CONTACT_50084], close 
clinical monitoring, and stoppi[INVESTIGATOR_004] .
There may  be unknown risks of bimagrumab
,which may  be serious.
Company Conf idential Information
[COMPANY_001] Confidential Page 45
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
3.7.2 Bimagrumab related risks
Acne
Data from the prior proof of concept study  in older adults with sarcopenia reported an 
incidence of acne in 10.5% (2/19) of patients administered two doses of 30 mg/kg 
bimagrumab. 
Program -wide, single and multiple dose studies in health y volunteers and patients with 
sarcopenia, sIBM and COPD cachexia demonstrated the occurrence of diffuse, transient acne 
on the face and scalp and less frequentl y on the back and chest in 18.3% of the population. 
Earlier studies showed an increased incidence with the highes t doses (Table 3-1). 
Conversel y,acne was not observed in the multiple dose study  (CBYM338X2102) after three 
i.v.doses of 3 or 10 mg/kg every  4 weeks.
Acne has been confirmed in these studies by [CONTACT_740135] . Treatment has 
been successful with good skin hygiene using a 4-10% benzoy l peroxide wash and over the 
counter topi[INVESTIGATOR_12969]. On occasion, aprescription, topi[INVESTIGATOR_740114] 
(i.e., minocy cline 100 mg bid), was recommend ed. However, early standard of care 
intervention is recommended in participants when acne presents.
Further analysis of skin reactions and their association with preexisting conditions, 
bimagrumab PK parameters, time to appearance from dosing and time to resolution will be 
performed in current and future studies. A possible mechanistic link between bimagrumab and 
skin reactions remains unclear.
Table 3
-1 Skin reactions consid ered possibly  related to bimagrumab from 
unblinded data*
Muscle Sy mptoms
Involuntary  muscle contractions, referred to as cramps, spasms or twitches, have been 
reported by [CONTACT_740136] 
(Table 3-2 ). 
The dose-frequency  of muscle symptoms is not linear. In the multiple dose study , spasms 
were reported by [CONTACT_31806] (of six) subject sreceiving three i.v.doses of 3 mg/kg, and six (of six) 
receiving 10 mg/kg and four (of six) in the combination i.v. and s.c. cohort (greatest drug 
exposure). Most muscle spasms throughout the clinical study  program have been mild in 
intensity , transient, painless, of short duration, and did not require medical treatment. Several 
cases of muscle spasms were moderate in severity .
Company Confidential Information
[COMPANY_001] Confidential Page 46
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
In early studies, a smaller percentage of muscle symptoms were seen in older healthy 
volunteers 70-[ADDRESS_1011381] (of 6) that received 3 mg/kg, while no 
cases were reported in the 
group receiving 30 mg/kg.
The etiology  and clinical meaning of these observations are not known. Similar symptoms 
have been reported with at least one other anabolic molecule, a beta-[ADDRESS_1011382] 
(Tomlinson et al 1990) and are commonly  reported by [CONTACT_740137]. Data on twitches and the effects on people receiving bimagrumab are detailed in the 
Investigator’s Brochure.
Table 3
-2 Muscle sy mptoms considered possibly  related to bimagrumab from 
unblinded data*
Company Confidential Information
[COMPANY_001] Confidential Page 47
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Reproductive organs
Data from CBYM338X2108 demonstrate no clinically  or statisticall y significant effect of 
bimagrumab on circulating testosterone levels and no effect on the pi[INVESTIGATOR_2117] -gonadal or 
pi[INVESTIGATOR_2117] -adrenal axes in either gender. Suppression of FSH levels in postmenopausal women 
and premenopausal women of non-childbearing potential has been observed with no 
associated safet y risk identified. All effects were transient and resolved after bimagrumab 
exposure ended. Semen analysis data from the multiple dose study suggest that three doses of 
10mg/kg have no effect on sperm count or quality  in males. 
Women of childbearing potential may participate 
in this study  as long as they use highl y 
effective contraception as detailed in Section 4.2 (Exclusion criteria).
Immunogenicity
It is possible that anti-drug antibodies could develop against bimagrumab, which could 
neutralize or clear the drug more rapi[INVESTIGATOR_2478] y and attenuate its efficacy . A treatment related 
anti-drug antibody  response has been observed in subjects treated with bimagrumab although 
it should be noted that high exposure to bimagrumab may mask the presence of an immune 
response. Nevertheless, there wasno evidence of an infusion or hypersensitivity  reaction that 
could be related to immunogenicity  or any sign of immune complex formation in the clinical 
trials performed so far. No positive signal in the immunogenicit y assay  was accompanied by  a 
change in the bimagrumab PK profile.
Lipase and amy lase elevations
Observations of dose-dependent, transient, sub-clinical elevations of lipase and/or amylase 
have been identified in several studies in the bimagrumab clinical program. The biological 
explanation for this temporal rise in pancreatic enzy mes seen in some individuals is not yet 
fully  understood.
As of [ADDRESS_1011383] been two confirmed cases of acute pancreatitis among 
approximately  1038 participants administered bimagrumab. There is no known association
among participants receiving bimagrumab between the temporary  elevations in lipase and/or 
amylase and an increased risk for pancreatitis. However, to reduce the potential risk of 
elevated pancreatic enzymes to study  participants, volunteers with elevated amylase and 
lipase will be excluded as per Section 4.2.
Participants will be monitored throug hout the study as detailed in 
theAssessment schedule.
Safet y monitoring guidance for participants who experience elevated lipase and/or amylase 
during the stud y is provided in Section 9.4.
Company Confidential Information
[COMPANY_001] Confidential Page 48
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
3.7.[ADDRESS_1011384] during the study 
over a period of 392 days (56 weeks). Additional samples for monitoring of any safet y 
findings are not included. Blood collection is not considered to be a risk for this population.
During the collection of blood samples, subjects may experience pain and/or bruising at the 
insertion site of the needle/catheter. Although rare, localized clot formation, infec tions and 
nerve injury  may occur. Lightheadedness and/or fainting may also occur during or shortl y 
after the blood draw. Patients will be observed following all blood draws and discharged only 
when the Investigator observes stable health status. In additio n, liquids by [CONTACT_220433], fruit juice or a similar product will be provided following the blood draw to 
replenish the blood volume removed.
Timings of blood sample collection are outlined in the Assessment Schedule, Section 8.1. 
Asummary  blood log is provided in the Site Operations Manual, together with instructions 
for all sample collection, processing, storage and shipment information. 
See Section 8.[ADDRESS_1011385] as fever, chills, urticaria, dyspnea, headaches , 
myalgia and/or hypotension. 
Aserious infusion reaction that results in anaph ylaxis is a rare event in monoclonal antibody 
therap y. If a severe hypersensitivity  reaction occurs, administration of bimagrumab should be 
discontinued and appropriate therap y initiated.
Diet-related
The daily  caloric deficit of 500 Kcal with approximately  45-50% calories from carboh ydrate, 
20-25% from protein and 30% from fatis a standard approach and is expected to induce
weight loss of approximately  450 gr (1 pound) per week over the treatment period. It may  also
enhance the effect of bimagrumab on body  composition and body  weight. The anabolic effect
of bimagrumab requires adequate protein intake. Given the daily  caloric deficit, 
the protein
intake is increased to 1.2 g/kg/day to ensure an adequate protein supply  for increasing lean
mass.
A daily  multivitamin/multimineral supplement is also recommended to ensure adequate intake 
of micronutrients involved in protein synthesis and glucose regulation.  Over-the-counter 
supplements will be recommended at doses commonly  consumed and recommended by
[CONTACT_740138] (for example, the US Institutes of Medicine). 
Noadverse effects are anticipated.
[COMPANY_001] Confidential Page 49
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Exercise -related
The ADA walking program is tailored to the type of population in this study  and is a gentle, 
easy to implement approach for physical activity . 
No adverse effects are anticipated.
Imaging
Dual -Energy X -ray Absorptiometry (DXA)
This clinical study  involves exposure to radiation from a DXA total body  scan. The radiation 
exposure by  [CONTACT_740139] y. 
The effective dose of a DXA whole body  scan on an adult is 2.[ADDRESS_1011386] from five DXA scans will be about 10.5 microSv. 
This amount of radiation is equivalent to approximately  14 days of background exposure 
(approx. 0.03 microSv per hour at sea level). For effect ive radiation doses under 3 mSv 
(300 mrem), the risk is considered to be minimal (Albanese et al 2003). Therefore, the 
radiation exposure in this study  involves minimal risk and is necessary  to 
obtain the research 
information desired (Stabin 2008). DXA measures are described as having no observable or 
biological effect and are similar to natural background levels of radiation in most countries ; 
thestudy  scans pose no safet y risk. 
4 Population
Approximately  sixty -eight (68) overweight/obese men and women 18 -75 years old (inclusive) 
with type [ADDRESS_1011387] (e.g.,checklist) of the eligibility  criteria must be stored with 
the source documentation at the study  site.
Deviation from an y entry criterion excludes a subject from enrollment into the study .
Company Conf idential Information
Company Confidential Information
[COMPANY_001] Confidential Page 50
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
4.[ADDRESS_1011388] be obtained before any  assessment is performed.
2.Male and female, age 18 to 75 years (inclusive), in stable health condition as determined
by[CONTACT_181938] , phy sical examination, vital signs, electrocardiogram, and
laboratory  tests at screening.
3.Type 2 diabetes, with an HbA1c between 6.5% and 10% (inclusive) at screening .
4.
Onone of the following anti-diabetes regimens with stable treatm ent for approximately
3months prior to randomization: 1) metformin monotherap y; 2)DPP4 inhibitor agent
monotherap y; 3) combination therap y of metformin and DPP4 inhibitor agent; 4) no
anti-diabetes therap y.
5.Body mass index (BMI) of 28.0 to 40 .0kg/m2(inclusive) at screening.
6.Body weight between 65 and 140 kg (inclusive) at screening, and with a stable body
weight (±5 kg) by [CONTACT_969]  (patient report) and stable physical activit y within 3 months
prior to screening b y history  (patient report) .
7.Able to communicate well with the investigator ; to understand and comply  with the
requirements of the study.
4.2 Exclusion criteria
Conditions related to safety : 
1.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female
after conception until the termination of gestation, and confirmed by a positive hCG
laboratory  test at screening .
2.Women of child- bearing potential, defined as all women physiologically  capable of
becoming pregnant unless they are using highl y effective methods of contraception during
dosing and for 6 months after stoppi[INVESTIGATOR_221954]. Highly effective
contraception methods include:
Total abstinence from heterosexual intercourse (when this is in line with the p referred
and usual lifesty le of the subject). Periodic abstinence (e.g. calendar, ovulation,
symptothermal, post-ovulation methods) and withdrawal are not acceptable methods
of contraception.
Female sterilization (surgical bilateral oophorectomy  with or without hysterectom y),
total hysterectomy  or tubal ligation at least six weeks before taking investigational
drug.  In case of oophorectom y alone, only when the reproductive status of the
woman has been confirmed by [CONTACT_104].
Male sterilization (at least 6 months prior to screening). For female subjects in the
study , the vasectomized male partner should be the sole partner for that subject .
Use of oral, injected or implanted hormonal methods of contraception or placement of
an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal
contraception that have comparable efficacy  (failure rate <1%), for example hormone
vaginal ring or transdermal hormone contraception .
In the case of oral contraception, women should be stable on the same pi[INVESTIGATOR_6522] a minimum 
of 3 months before taking theinvestigational drug.
[COMPANY_001] Confidential Page 51
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Women are considered post-menopausal and not of child- bearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age-appropriate, history  of vasomotor symptoms) or have been sterilized as specified 
above. 
3.Any chronic active infection (e.g., HIV, hepatitis B or C, tuberculosis, etc) or has received
anti-HCV treatments within the previous 6 months. Patients receiving chemoprophy laxis
for latent tuberculosis infection are eligible for the study .
4.History  of or known hypersensitivity  to monoclonal antibodies or drugs similar to the
study  drug.
5.History  of multiple and recurring allergies or allergy  to the investigational
compound/compound class being used in this study.
6.Chest pain, severe shortness of breath, or occurrence of other safet y concerns during the
screening or baseline assessments.
Diabetes related conditions: 
7.Diabetes other than type 2, such as type 1 diabetes, surgically  induced -diabetes ,"brittle"
type 2 diabetes as per investigator judgment, history  of severe hypoglycemic epi[INVESTIGATOR_740115] y ear preceding screening, known hy poglycemic unawareness.
Liver or pancreas related conditions:
8.Abnor mal liver function tests such as SGOT (AST), SGPT (ALT), alkaline phosphatase,
or serum bilirubin (except Gilbert’s Disease) , or abnormal lipase and/or amylase.
Theinvestigator should be guided b y the following criteria:
a.Any single transaminase may  not ex ceed 3x the upper limit of normal (ULN).
b.A single parameter elevated up to and including 3x UL N should be re-checked
as soon as possible, and alway s prior to enrollment/randomization, to rule out
any laboratory error.
c.If the total bilirubin concentration is increased above the ULN, total bilirubin
should be differentiated into the direct and indirect reacting bilirubin. In any
case, serum bilirubin should not exceed the value of 1.6 mg/dL (27μmol/L).
d.Screening or baseline levels of lipase and/or amy lase ≥ 2x UL Nare
exclusionary . Initial tests in either lipase or amy lase of ≥ 2x UL N should be re -
checked as soon as possible to confirm lab values, and must be available prior
to randomization. Patients with confirmed lipase and/or amy lase ≥ 2x UL N at
screening or baseline are excluded.
9.Known history  or presence of severe active acute or chronic liver disease (e.g., cirrhosis)
or conditions with hepatotoxic potential (e.g. known gallbladder or bile duct disease, acute
or chronic pancreatitis , or exocrine pancreat ic insufficiency ).
[COMPANY_001] Confidential Page 52
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Other conditions:
12.Any medical condition or laboratory  finding during screening (e.g. an unexplained or
clinically  significant laboratory result), which, in the opi[INVESTIGATOR_871], may
interfere with participation in the study , might confound the results of the study , or pose
an additional safet y risk in administering bimagrumab.
13.History  of malignancy  of any organ system (other than localized basal cell carcinoma of
the skin), treated or untreated, within the past 5 years, regardless of whether there is
evidence of local recurrence or metastases.
14.Active alcohol or drug abuse, or participation in an alcohol or drug treatment program
within 1 year prior to screening.  Subjects having successfully  completed an alcohol or
drug treatment program > 1 year prior to screening with sustained abstinence may be
eligible.
15.Confirmed diagnosis of current, significant psychiatric disease (e.g. dementia,
Alzheimer’s disease, schizophrenia, depression or bipolar disorder).  Individuals with
adequatel ytreated depression and stable treatment at least 3 months prior to screening are
eligible for enrollment .
16.Chronic kidney  disease [estimated glomerular filtration rate (GFR) < 30 mL/min].
17.Patient plans to move out of the study  area within 12 months, or be out of the study  area
for > 4 weeks, continuously .
18.History  of any  type of bariatric procedure .
Temporary  Exclusion cri teria :
Subjects excluded for one of the temporary  medical conditions listed below may be 
rescreened after a period that is considered clinically  relevant by  [CONTACT_093].  The subject
will need to re-sign informed consent and the full screening visit must be repeated under a 
new subject number .
20.Use of prohibited medications (found in Section 5.2).
21.Significant acute illness such as urinary  tract infection or upper respi[INVESTIGATOR_740116] (2) weeks prior to screening .
Company Confidential Information
Company Conf idential Information
[COMPANY_001] Confidential Page 53
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
22.Men with low fasting morning testosterone (<250 ng/dl) at screening; men receiving
testosterone replacement therap y for low testosterone are eligible if on a stable dose of
testosterone for a minimum of 3months and if their testosterone level is in the normal
range on [ADDRESS_1011389] one month apart and not more than 6 months apart,
the second one being performed at screening.
23.Systolic blood pressure > 180 or < 90 mmHg or diastol ic blood pressure > 100 or
<
[ADDRESS_1011390] 30 day s (or [ADDRESS_1011391] is expected to return to baseline, whichever is longer, or longer if
required by [CONTACT_32594]) from a clinical trial involving an investigational drug or off-
label use of a drug, or are concurrentl y enrolled in any other type of medical research
judged to be scientifically  or medicall y incompatible with this study .
25.Uncontrolled thyroid disease.  Hypoth yroid subjects with euthyroidism on stable thyroid
replacement therap y for at least 3 months prior to screening are allowed.
26.Significant change in cigarette smoking within 3 months of screening, as judged by [CONTACT_31035].
27.Use of any anti-obesit y medications, nutritional supplements or over the counter products
for weight loss within 3 months of screening. Use of medications known or suspected to
induce weight gain, such as some anticonvulsant and psychotropic medications (excluding
anti-depressant medication, refer to point 15) within 3 months of screening.
28.Use of skeletal muscle anabolic agents in any form such as medications, hormones
(except stable testosterone replacement therapy  for at least 3 months for hypogonadal
men), over thecounter products and nutritional supplements (other than protein) that are
labeled as muscle anabolic agents for [ADDRESS_1011392] yle modifications targeted for
weight loss or diabetes control started within 3 months of screening.
Refer to Section 8.3 (Subject Screening) for information regarding re -screening. 
Refer to Section 8.[ADDRESS_1011393] of safet y assessment s.
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
5 Restrictions for Study  Subjects
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of the restrictions outlined in this section.
5.1 Contraception requirements
Women of childbearing potential are eligible for this study if they use highl y effective 
methods of contraception during dosing and for 6 months after stoppi[INVESTIGATOR_14917]. 
Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the subject.
Periodic abstinence (e.g., calendar, ovulation, s ymptothermal, post -ovulation methods)
and withdrawal are not acceptable methods of contraception.
[COMPANY_001] Confidential Page 54
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Female sterilization (surgical bilateral oophorectomy  with or without hysterectom y), total
hysterectom y or tubal ligation at least six weeks before taking stu dy treatment.  In case of
oophorectom y alone, only when the reproductive status of the woman has been confirmed
by [CONTACT_104] .
Male sterilization (at least 6 months prior to screening). For female subjects in the study ,
the vasectom ized male partner should be the sole partner for that subject.
Use of oral, injected or implanted hormonal methods of contraception or placement of an
intrauterine device (IUD) or intrauterine s ystem (IUS) or other forms of hormonal
contraception that have comparable efficacy  (failure rate <1%), for example hormone
vaginal ring or transdermal hormone contraception. I n case of use of oral contraception,
women should be stable on the same contraceptive medication for a minimum of [ADDRESS_1011394] will not reliably  comply ,they 
should not be entered or continue in the study .
5.2 Prohibited treatment
Use of skeletal muscle anabolic agents in any form such as medications, hormones, over
the counter products and nutritional supplements (other than protein) that are labeled as
musc le anabolic agents.
Anti- obesity  medications, nutritional supplements, dietary  interventions other than
described in the protocol, or over the counter products for weight loss.
Chronic systemic steroid treatment or systemic steroids for > 7 consecutive day s for
worsening of an underl ying condition are not allowed during the study  and within 4 weeks
of screening.
Any anti diabetic medication other than metformin or DPP4 inhibitor agent. Injectable
drugs such as exenatide or pramlintide are prohibited; insulin is allowed for up to one
week at a time to correct for acute hy pergl ycemia .
Any product or medication known or suspected to cause weight gain, unless it is a stable
anti-
depressant therap y for at least [ADDRESS_1011395] calorie restricted diet with a daily  deficit of 
approximately  500 kcal andapproximately  45-50% calories from carbohydrate, 20 -25% from 
protein and 30% from fatintake throughout the study , inkeepi[INVESTIGATOR_740117] (at least 1.2 g/kg/ body  w eight) for anabolism 
(WHO guidelines 2015 ).The amount of calories will be determined by  a dietitian or ph ysician 
for every  patient according to their height, weight and calculated basal metabolism. A copy  of 
[COMPANY_001] Confidential Page 55
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
the diet with content and nutritional information will be provided to the Sponsor prior to study  
start upon request .
Once enrolled and throughout the study  period, site person nel will query study  patients to 
determine if there has been a change in dietary  habits and to encourage dietary intake that will 
promote weight loss.  Dietary  monitoring will occur via:
Monthly  dietary  counseling visits at which time 
a 24 hour recall will be obtained
Collection of 3- day food records at 3 time points during the stud y
One telephone or in-person
contact [CONTACT_740140], approximately  midway  between counseling
visits, to obtain a 24- hour dietary  recall and reinforce lifest yle intervention.
Subjects will be advised to consume a dail y multivitamin/multimineral supplement.  
Smoking is discouraged but not prohibited for participation in this trial. Patients should refrain 
from smoking for one hour prior to study  visits and during the study  visits.
On Day 1, no breakfast will be provided. Meals should be similar in caloric content and 
macronutrient distribution for all patients on the day  of dosing.
5.[ADDRESS_1011396] numbering, prescribing/dispensing and taking study  treatment are 
outlined in the Site Operations Manual and Pharmacy  Manual .
Refer to Section 5.3 ‘Dietary  restrictions and smoking’ for details of dosing and food intake.
6.1.1 Investigational treatment and control drugs
The investigational drug, bimagrumab , 150 mg LIVI (liquid in vial), will be prepared by 
[CONTACT_740141]. Study  drug 
preparation will be detailed in a separate pharmacy  manual. Placebo will be a D5W infusion 
supplied by  [CONTACT_779]. 
Table 6-1 Overview of study  medication
Study drug name [CONTACT_740163] (e.g., 
approximate size, color, etc.)PackagingProvided 
by 
[CONTACT_740142]338 
(bimagrumab)liquid in vial water infusion open labeled bulk 
medication[COMPANY_001]
Placebo Liquid water infusion Site
[COMPANY_001] Confidential Page 56
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Study  drugs must be received at the study  site by a designated person, handled and stored 
safel y and properl y, and kept in a secure location to which only the Investigator and 
designated staff have access. Upon receipt, the study  drugs should be stored according to the 
instructions specified on the drug labels. Storage conditions must be adequatel y monitored 
and appropriate temperature logs maintained as source data. Appropriate documentation of the 
patient specific dispensing process must be maintained. Bulk medication labels will be in the 
local language, will comply  with the legal requirements of each country , and will include 
storage conditions for the drug but no information about the patient.
Note: To maintain the blind, the investigational treatments will be prepared by [CONTACT_29646]/designee, the bags will be covered by [CONTACT_740143], and the investigational 
treatment will only be administered by [CONTACT_740144] t 
allocation .
All drug supplies are to be used only for this protocol and not for any other purpose. 
Unless specifically  instructed by [CONTACT_5343], the Investigator must not destroy any drug labels, 
or any partly used or unused drug supply . Only after receivi ng a written authorization by 
[CONTACT_5343], the Investigator/designee will send all the unused and partly used drug supplies ,as 
well as the empty  containers, to the address provided at the time of authorization for 
destruction.
Sponsor qualified medical personnel will be readily  available to advise on trial related 
medical questions or problems.
6.1.2 Additional study  treatment
Not applicable.
6.2 Treatment arms
Patients will be assigned to one of the following 2 treatment arms in a ratio of 1:1 .
Study  treatments a re defined as:
Bimagrumab 10 mg/kg up to maximum 1200 mg ,every  4 weeks (12 doses)
Placebo, every  4 weeks (12 doses)
6.[ADDRESS_1011397] of care,but 
are restricted to the following : 
Either increased or decreased dosage , or discontinuation, of current medication is allowed
under the guidance of a medical professional;
The add -on of a second medication is allowed but restricted to metformin or
DPP4 -inhibitor;
Insulin, as an acute treatment for severe or uncontrolled hy pergl ycemia, such as during an
acute illness, is allowed but restricted to one week only ;
[COMPANY_001] Confidential Page 57
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
The Inves tigator must emphasize to the subjects the importance to communicate ANY change 
in the background medication. In particular, the Investigator must inform the subject sthat 
ANY change in the anti-diabetes medication that IS NOT LISTED above, will cause the 
subject to discontinue study  treatment. Any modification to the background therap y during 
study  participation must be reported by  [CONTACT_737].
6.5 Treatment assignment and randomization
Treatment is assigned by [CONTACT_740145]’s
baseline BMI. The strata have the following randomization numbers: 
BMI between 28 .0kg/m2and 33.0 kg/m2(inclusive): 5101 – 5150
BMI between 33 .1 kg/m2and up to 40 .0kg/m2(inclusive): 5201 – [ADDRESS_1011398] been randomized to receive.  
The Patient number assigned to a patient at screening remains the unique identifier for the 
patient throughout the study .  For information on patient numbering, please see ‘Subject 
numbering’ section in the SOM.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and conceal ed from subjects and investigator staff. 
Arandomization list will be produced by,or under the responsibility of,[COMPANY_001] Drug 
Supply  Management using a validated system that automates the random assignment of 
treatment arms to randomization numbers in t he specified ratio.
BMI was selected as a stratification parameter as it is an important predictor of response on 
parameters of body  composition/body  weight and HbA1c (internal data). The expected 
median value for BMI in this patient population is 33 kg/m2(internal data); therefore , 2 strata 
above and below/inclusive of the median will ensure a balanced representation of patients 
between placebo and active drug in each strata, i.e. strata of approximately  similar size 
between the [ADDRESS_1011399] 
estimation in both strata.
The randomization scheme for patients will be reviewed and approved by a member of the 
Randomization Office.
Follow the details outlined in the Site Operations Manual regarding the process and timing of 
treatment assignment and randomization of subjects.
[COMPANY_001] Confidential Page 58
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
6.[ADDRESS_1011400] -and investigator -blinded study . Subjects and investigators will remain 
blinded to study  treatment throughout the stud y, except where indicated below.
Site staff
With the exception of any unblinded site staff identified below, all site staff (including study 
investigator and study  nurse) will be blinde d to study  treatment throughout the study .
Unblinded pharmacist
Unblinding a single patient at site for safet y reasons (necessary  for patient management) will 
occur via an emergency  system in place at the site (see Section 6.8 Emergency  breaking of 
assigned treatment code).
IMPORTANT: Drug product will be supplied in bulk. Due to the difference in preparation 
methods between the active and placebo treatments, an unblinded pharmacist or other 
qualified trained personnel, who is independent of the study team, will be required. 
This unblinded pharmacist will receive treatment allocation cards from Drug Suppl y 
Management with the appropriate treatment allocation numbers. Appropriate measures must 
be taken by [CONTACT_647940]. Any potential visible difference in treatments will be concealed 
by [CONTACT_740146].
Sponsor staff
The following unblinded sponsor roles are required for this study :
Unblinded field monitor(s)
Unblinded clinical staff managing drug re -supply to site
Unblinded sample anal yst(s) (PK blood)
The unblinded field monitors are required to review drug accountabilit y and allocation at site. 
The unblinded monitors are not provided with a randomization list directl y but will be 
unblinded through review of source documentation compi[INVESTIGATOR_740118] d pharmacist, 
which details treatment allocation to individual subjects. The unblinded monitors will also be 
able to review the treatment allocation cards/randomization list provided to the unblinded 
pharmacist. 
Sponsor clinical staff are required to assi st in the management and re -supply  of investigational 
drug product. These individuals are not provided with randomization lists directl y, but may  be 
unblinded through communication of drug re- supply  needs via the unblinded site pharmacists.
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office), to facilitate analy sis of the samples. The sample analy sts will provide 
the sample data to the study  team under blinded conditions unless otherwise allowed.
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unblinded information with the rest of the clinical team as appropriate for 
internal decision purposes, as outlined in Table 6-2. For example, unblinded summaries and 
unblinded individual data can be shared with the team for interim analy ses.
[COMPANY_001] Confidential Page 59
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Study  programmers and other personnel involved in study  data analysis (e.g. biomarker 
expert) are allow ed to access treatment assignment information for the purpose of conducting 
interim anal yses.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study or the project at 
the time of interim anal yses while the study is ongoing.
All unblinded personnel will otherwise keep randomization lists and data or information that 
could unblind other study team members confidential and secure except as described abo ve.
Following final database lock all roles may  be considered unblinded.
Table 6-[ADDRESS_1011401] 
generatedTreatment 
allocation & 
dosingSafety event (single 
subject unblinded)Interim 
Analysis 
Subjects B B UI B
Site staff B B UI B
Unblinded site staff (see text for 
details) B UI UI UI
Drug Supply and Randomization 
OfficeUI UI UI UI
Unblinded sponsor staff (see text 
for details)B UI UI UI
Statistician/statistical 
programmer/data analystsB B UI UI
Independent committees used for 
assessing interim resultsB UI UI UI
All other sponsor staff not 
identified aboveB B UI UI
B Remains blinded
NA Not applicable
UI Allowed to be unblinded on individual patient level
6.[ADDRESS_1011402] via the following route of 
administration: i.v. by [CONTACT_250877].
Administrations will be performed at the study site. See the Site Operations Manual for 
further details.
Sponsor qualified medical personnel will be readily  available to advise on trial related 
medical questions or problems.
[COMPANY_001] Confidential Page 60
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
6.[ADDRESS_1011403] who presents with an emergency  
condition. A complete set of emergency  code break cards will be provided to the investigator 
site(s) and a complete set will be available at [COMPANY_001]. All code break cards must be retained 
until the end of the study  and returned to [COMPANY_001]. They  must be stored in a secure place but 
be accessible to the investigator [ADDRESS_1011404] , with the details of study treatment covered 
by a removabl e, scratch -off cover. In an emergency , the scratch- off cover can be removed to 
determine the treatment. The scratch -off covers are not to be removed for any reason other 
than an emergency . When the investigator removes the scratch -off cover he/she must note the 
date, time, and reason for removing it and retain this information with the case report form 
documentation. The unblinded treatment code must not be recorded on the CRF.
Theinvestigator must also immediately  inform the study  monitor that the code has been 
broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the code break cards at any time in case of emergency .   Th e investigator will 
need to provide: 
protocol number
study  drug na me (if available)
subject number.
In addition, the investigator must provide oral and written information to inform the subject
how to contact [CONTACT_5657]/her backup in cases of emergency  when he/she is unavailable to ensure that 
un-blinding can be performed at an y time.
An assessment will be done by [CONTACT_740147]-blinding to assess whether or not study  treatment should be discontinued for a given 
subject and, if applicable, whether the subject can continue into the next trial phase (e.g., an 
unblinded extension).
6.[ADDRESS_1011405] section of the eCRF.
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all 
subjects treated with bimagrumab, as detailed in Section 8.7 .
[COMPANY_001] Confidential Page 61
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
6.10 Recommended treatment of adverse events
Muscle sy mptoms can be addressed with light self -massage of the involved area concentrating 
on improving circulation and relaxing muscle tissue. If excessive or prolonged soreness 
presents, then acetaminophen may  be used as needed.
Acne may be treated with a face wash containing 4-10% benzoy l peroxide and over the 
counter topi[INVESTIGATOR_12969]. If needed, a prescription topi[INVESTIGATOR_35786] (i.e., antibiotics) or oral 
antibiotic (i.e., minocy cline 100 mg bid) may  be recommended at the Investigator’s discretion. 
Early intervention is recommended when acne presents.
Diarrhea may be treated with over the counter remedies. In cases of prolonged occurrence, 
other treatments may
 be used at the Investigator’s discretion.
Although not expected, any acute allergic reactions should be treated as needed using 
conventional counter measure therapi[INVESTIGATOR_220410] (including but not limited to epi [INVESTIGATOR_238], 
antihistamine, corticosteroid, intravenous supplies, crystalloid, an oral airway , bag and mask, 
and supplemental oxygen). In the case of a serious adverse event in which decreasing the 
systemic concentration of bimagrumab may be of clinical benef it, the investigator should 
consider plasmapheresis. Study  sites should not feel constrained in any way from providing 
necessary  medical intervention.
Adverse events related to underly ing disease of T2D:  h ypogl ycemia or hy pergl ycemia events 
that are clinically significant based on the judgment of the principal investigator [INVESTIGATOR_740119].
Medication used to treat AEs must be recorded on the Concomitant medications/Signific ant 
non-drug therapi[INVESTIGATOR_50061].
Elevated lipase and amylase levels that meet AE criteria should be monitored and managed
according to 
Section 9.[ADDRESS_1011406] to notify  the study  site about any NEW and 
changes to current medications he/she takes AFTER the start of the study . 
All prescription medications, over-the-counter drugs and significant non-drug therapi[INVESTIGATOR_014] 
(includin g physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry  criteria prior to the start of the study  and during the study , 
must be recorded on the Concomitant medications/ Significant non-drug therapi[INVESTIGATOR_740120] n of 
the eCRF. 
Should a subject have an incidental and limited need for a medication to be taken within the 
restricted pre-dose timeframe (e.g.,ibuprofen for a headache, antibiotic prophylaxis prior to 
dental surgery , etc.), the sponsor should be advised , as administration of any concomitant 
medication may require the subject to be discontinued. 
[COMPANY_001] Confidential Page 62
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Administration of acetaminophen on an occasional basis is acceptable, but must be 
documented. Medication entries should be specific to trade name, the single dose and unit, the 
frequency  and route of administration, the start and discontinuation date and the reason for 
therap y.
Medications allowed in the study as chronic therapy :
Low dose aspi[INVESTIGATOR_9022].
Oral anti -diabetic therapy  (limited to metformin and/or DPP4 inhibitor agent), with stable
treatment for approximately  3 months prior to randomization, for diabetes management
during the trial. Insulin is allowed for one week only  in case of acute deterioration of
glycemic control.
Stable regimen of testoste rone replacement therapy  for at least 3 months prior to
randomization.
Thyroid replacement therapy  that is stable for at least 3 months prior to randomization.
Antihy pertensive medication must be on a stable regimen for at least 3 months prior to
randomiz ation.
Medications for d yslipi[INVESTIGATOR_740121] 3 months prior to randomization.
Vitamin D and multivitamin/mineral supplementation (see below)
Antidepressant medications must be stable for at least 3 months prior to randomization.
Chronic therap y for hyperuricemia must be stable for at least 3 months prior to
randomization.
Other chronic therap y medications not listed above require Sponsor approval
6.13 Vitamin and mineral supplementation
The subject must consume anoral multivitamin/multiminera l supplement.
In subjects with 25- OH vitamin D level between 12.0 and 50.0 ng/mL inclusive at
screening:
Daily  administration of vitamin D as part of the multivitamin/multimineral supplement
(800 IU to 4000 IU, D3 preferable but D2 also acceptable per local availability ); or,
Equivalent weekl y or monthly  formulation if deemed to be of advantage for the
individual subject’s compliance.
In subjects with 25 -OH vitamin D level ≥50.0 ng/mL  at scr
eening :supplementation
recommendations may be made at the investigator’s discretion.
In subjects with 25- OH vitamin D level <12.0 ng/mL  at screening and with no sy mptoms
of osteomalacia or low serum calcium: administration of loading dose of oral vitamin D
(recommended minimum 50 000 IU of vitamin D3, but according to local guidance) will
be allowed. Different formulations of vitamin D3 are allowed based on the approved
therap y in the subject ’s country . Vitamin D2 is permitted where D3 is not available.
[COMPANY_001] Confidential Page 63
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
[ADDRESS_1011407] if, on balance, he/she 
believes that continuation would be detrimental to the subject 'swell-being.
Study  treatment must be discontinued for an individual subject under the following 
circumstances
:
Withdrawal of consent
An infusion reaction that is considered severe
One or more s ymptomatic hy poglycemic event s necessitating third part y rescue and
suspected to be related to study  drug; if diabetes medication can be appropriately  reduced,
the study  drug may  be resumed after stabilization of FPG at the Investigator's discretion
A serious adverse event (SAE) though t to be related to study  drug
Pregnancy : a positive urine pregnancy  test after start of study  treatment requires
immediate interruption of study  treatment until serum hCG is performed and found to be
negative
Any protocol deviation that results in a signif icant risk to the subject ’s safety
Emergence of one or more adverse events that in the judgment of the investigator, taking
into account the subject ’s overall status, prevent the subject from safel y continuing in the
study
Investigational treatment may be discontinued under the following circumstances:
Breaking of the blind (inadvertentl y or for emergency reasons)
Use of prohibited treatment as described in the protocol
Subjects who discontinue study  treatment should NOT be considered withdrawn from the 
study UNLESS they withdraw their consent. They  should return approximately  [ADDRESS_1011408] dose for the EoT visit (Visit 113). The EoS visit (Visit 199) should be scheduled 
[COMPANY_001] Confidential Page 64
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
4weeks after EoT. If they fail to return for these assessments for unknown reasons, every 
effort should be made to contact [CONTACT_15026] 7.4.
7.[ADDRESS_1011409]: 
Does not want to particip ate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e
-mail, 
letter) to understand the primary  reason for the subject’s decision to withdraw his/her consent 
and record this information.
Study  treatment must be discontinue d and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_5366] -up. 
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment schedule ( Table 8-1).
[COMPANY_001] will continue to keep and use collected study  information (including any data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law. 
For US: All biological samples not yet analyzed at the time of withdrawal may still be used 
for further testing/analy sis in accordance with the terms of this protocol and of the informed 
consent form.
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by [CONTACT_1289]. They  will be stored according to 
applicable legal requirements.
7.[ADDRESS_1011410] to follow -
up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withd raw, the investigator should show "due diligence" by 
[CONTACT_762] , e.g.,dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to follow -
up until his/her sc heduled end of study  visit would have occurred.
7.5 Stud y Stoppi[INVESTIGATOR_740122], the study  will be placed on hold and, upon review of 
study  data by [CONTACT_740148] y team and discussion with the investigators ,
may be terminated or the dose level re -evaluated.
Data from this study  is judged by  [CONTACT_740149] a clinicall y
significant risk of using bimagrumab in the diabetic obesity  patient population.
[COMPANY_001] Confidential Page 65
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Two or more subjects develop at least one event of sy mptomatic hy poglycemia
necessitating rescue that is not self -administered , and judged to be related to study  drug.
Two or more subjects develop a significant hy persensitivity  reaction (grade severe )
believed to be related to bimagrumab treatment.
The Sponsor unilaterall y requests a stoppage.
7.6 Early study  termination by  [CONTACT_740150]. This may include 
reasons related to the benefit/ risk assessment of participatin g in the study , practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. Should this be necessary, 
patients must be seen as soon as possible and treated as a prematurel y withdrawn patient. 
Theinvestigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the patient's interests. The investigator 
will be responsible for informing IRBs/IECs of the early termination of the trial.
[ADDRESS_1011411] month 
ofthe treatment period since a visit needs to be performed at Week 2 to comply  with the 
safet y monitoring for circulating amylase and lipase .
The Assessment Schedule below lists all of the assessments and indicates with an “x” the 
visits when they are performed. All data obtained from these assessments must be supported 
in the patient’s source documentation. Assessments marked with an “S” should be assessed 
and documented in the patient’s source documentation but no data needs to be entered into the 
eCRF. 
Patients should be seen for all visits on the designated day as specified in theAssessment 
Schedule. Until randomization ,the visits should be calculated relative to the calendar date of 
the previous visit. After randomization
,visits should be calculated relative to the calendar 
date of the randomization visit.
[COMPANY_001] Confidential Page 66
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Table 8-1 Assessment schedule
Epoch Screening Treatment and Primary Follow -Up
Visit Name [CONTACT_442154]1Treatment
Visit Numbers 1 2 101 115 102 103 104 105 106 107
Days -21 to -8 - 7 to -1 1 14 28 56 84 112 140 168
Time (post -dose) - - Pre-dose 0min 45min6- - - - - - Pre-dose 0min 45min6
Informed consent X
Genetic Informed Consent X
Inclusion / Exclusion criteria S S2
Subjects domiciled3S
Study drug administration X X X X X X X
Demography X
Medical history/current medical conditions X
Concomitant therapi[INVESTIGATOR_014] X X X X X X X X X X
Body Heig ht X
Body W eight X X X X X X X X X
Waist circumference X X X
Hip measurement X X
Vital Signs X X X X X X X X X
Physical Examination S S S
ECG evaluation X X
Alcohol Test and Drug Screen S
Hepatitis and HIV Screen S
Pregnancy test X X X X X X X X X
Fasting insulin and glucose5X X
HbA1 c X X X
Mixed Meal Tolerance Test5See Table 8 -2below
Blood chemistry5X X X X X X X
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 67
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Epoch Screening Treatment and Primary Follow -Up
Visit Name [CONTACT_442154]1Treatment
Visit Numbers 1 2 101 115 102 103 104 105 106 107
Days -21 to -8 - 7 to -1 1 14 28 56 84 112 140 168
Time (post -dose) - - Pre-dose 0min 45min6- - - - - - Pre-dose 0min 45min6
Hematology X X X
Urinalysis X X
25-Hydroxy Vitamin D X X
Testosterone X
TSH X
FSH LH X X
Immunogenicity X X
PK blood collection X X X X X
DXA scan X X X
Adverse events X
Dietary Counseling8X X X X X X X X X
3-day Food Record S S
24-hour recall dietary assessment10X X X X X X X X
Study completion information
Comments X
Company Confidential Information
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 68
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Epoch Treatment & Primary Follow -up
Visit Name [CONTACT_740164] -Up End Of Study
Visit Numbers 108 109 110 111 [PHONE_15446] 199
Days 196 224 252 280 308 336 364 392
Time (post -dose) - - - - Pre-dose 0min 45min6- - -
Informed consent
Genetic Informed Consent
Inclusion / Exclusion criteria
Subjects domiciled3
Study drug administration X X X X X
Demography
Medical history/current medical conditions
Concomitant therapi[INVESTIGATOR_014] X X X X X X X X
Body Height
Body Weight X X X X X X X X
Waist circumference X X
Hip measurement X X
Vital Signs X X X X X X X X
Physical Examination S S
ECG evaluation X
Alcohol Test and Drug Screen 
Hepatitis and HIV Screen
Pregnancy test X X X X X X X
Fasting insulin and glucose5X X
HbA1 c X X
Mixed Meal Tolerance Test5See Table 8 -2below
Blood chemistry5X X
Hematology X X
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 69
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Epoch Treatment & Primary Follow -up
Visit Name [CONTACT_740164] -Up End Of Study
Visit Numbers 108 109 110 111 [PHONE_15446] 199
Days 196 224 252 280 308 336 364 392
Time (post -dose) - - - - Pre-dose 0min 45min6- - -
Urinalysis X X
25-Hydroxy Vitamin D X
Testosterone
TSH 
FSH LH X X
Inflammatory markers X X
Immunogenicity X X
PK blood collection X X X X X X
DXA scan X X
Adverse events X
Dietary Counseling8X X X X X X
3-day Food Record S
24-hour recall dietary assessment10X X X X X X
Study completion information X
Comments X
Company Confidential Information
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 70
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
1Assessments expected at Baseline can be done on separate days between Day -[ADDRESS_1011412] to be re-checked at baseline (refer to Section 4.2 )
3Optional to be domiciled prior to day [ADDRESS_1011413] early discontinuation, visit assessments to be perform edfor the End of Treatment (EoT) visit
10See Table 8 -3for schedule of 24 -hour recall dietary assessments performed in between monthly sitevisits
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 71
Amended Protocol Version v05 (Clean) Protocol No. CBYM338X2211
Table 8-[ADDRESS_1011414]
Epoch Visit Name [CONTACT_740165] -Up Treatment101 10min* X
30min X
60min X
90min X
120min X
150min X
180min X
1071680min* X
30min X
60min X
90min X
120min X
150min X
180min X
1133360min* X
30min X
60min X
90min X
120min X
150min X
180min X
* Sample collection must be performed while subject is fasted prior to start of meal ingestion
Table 8-3 24-hour dietary  recall
Epoch Treatment And Primary Follow -Up
Visit Name [CONTACT_740166] 14 42 70 98 126 154 182 210 238 266 294 322
24-hour recall dietar y assessment via
telephone call or in-person visitxxxx x x x x x x x x
[COMPANY_001] Confidential Page 72
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.2 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent.
Informed consent must be obtained before conducting any study -specific procedures (e.g.,all 
of the procedures described in the protocol). The process of obtaining informe d consent must 
be documented in the subject source documents. 
[COMPANY_001] will provide to investigators a proposed informed consent form that complies with 
the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for this 
study . The informed consent form will also include a section related to optional future 
research which will require a separate signature [CONTACT_232150].  
Any changes to the proposed consent form suggested by  [CONTACT_740151] t o by 
[CONTACT_111908] I RB/IEC.
[COMPANY_001] will review the investigator’s proposed informed consent form to ensure it complies 
with the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for 
this study . Any further changes to the proposed consent form suggested by [CONTACT_232123] b y [COMPANY_001] before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochur e (IB). This information will be included in the patient 
informed consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile of the investigational drug that is identified 
between IB update s will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and then must be discussed with the patient.
Ensure subjects are informed of the contraception requirements outlined in Section 4.2
(Exclusion criteria) and in Section 5.1 (Contraception requirements).
A copy  of the approved version of all consent forms must be provided to the [COMPANY_001] monitor 
after IRB/IEC approval.
8.[ADDRESS_1011415] if s/he fails the initial screening; however, 
each case must be discussed and agreed with the Sponsor on a case -by-case basis.
Company Confidential Information
[COMPANY_001] Confidential Page 73
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Information on what data should be collected for screening failures is outlined in the Site 
Operations Manual.
Inclusion/exclusion criteria assessment will not be entered in the CRF, however, data should 
be available as Source data.
8.[ADDRESS_1011416] demographics/other baseline characteristics
Subjec t demographic and baseline characteristic data will be collected on all subjects and 
include: date of birth, age, sex, race, predominant ethnicity .  Relevant medical history /current 
medical conditions data will also be collected until signature [CONTACT_43998].  Details are 
outlined in the Site Operations Manual.
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to the informed consent signature.
8.4.[ADDRESS_1011417] and Drug Screen 
Subjects will be tested for substances of abuse (e.g., alcohol, amphetamines, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cocaine, cannabinoids, and opi[INVESTIGATOR_858]). 
Results will be available as source data and will not be recorded within the eCRF.
8.4.[ADDRESS_1011418] be tested for Hepatitis B, Hepatitis C, and HIV at the screening visit. 
Hepatitis B will be evaluated using the Hepatitis B surface antigen (HBsAg). Screening for 
Hepatitis C will be based on HCV antibodies and if positive, HCV RNA levels should be 
determined . Evaluation for HIV positive status should be performed, and, if positive, 
confirmation by a second technique available at the laboratory  site, e.g., Western blot or as 
specified b y local regulation.
Results will be available as source data and will not be recorded within the clinical database.
8.4.3 Testosterone and TSH
The following hormones will be measured at screening only: total testosterone (for males 
only) and thyroid stimulating hormone (TSH). If TSH is abnormal, free thyroxine (free T4 -
not total T4) should be reported. For testosterone refer to Exclusion criteria for more details.
8.5 Efficacy  / Pharmacody namics
Pharmacod ynamic assessments are specified below, with the methods for assessment and 
recording specified in the Site Operations Manual (SOM). Assessments will be 
performed/samples collected at the time point(s) defined in the Assessment schedule .
 DXA images will be centrall y read b y a CRO.
Pharmacod ynamic (PD) samples will be obtained and evaluated in all patients.
Company Confidential  
Information
[COMPANY_001] Confidential Page 74
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.5.1 Diabetes parameters
[IP_ADDRESS] Fasting insulin and glucose
Samples for fasting insulin and glucos e will be collected after a fast of approximately 
12hours at time points specified in the Assessment schedule . 
The Homeostatic model assessment 2 –insulin resistance index (HOMA2 -IR)is a derived 
insulin resistance index that must be calculated by [CONTACT_740152] . 
Please refer to the SOM for the details on the calculation.
The quantitative insulin -sensitivity  check index (QUICKI)is another insulin resistance index 
that will be calculated at the end of the study  and will not be entered in the CRF
(Yoko yama et al 2004; Hrebícek et al 2002 ) .
[IP_ADDRESS] HbA1c
HbA1c will be measured at time points defined in the Assessment schedule . 
[IP_ADDRESS] Meal Tolerance test and Matsuda Index
The meal tolerance test will be performed in the morning, after afast ofapproximately 12hours.  
The meal will consist of a mixed liquid -solid food and frequent blood sampling will be conducted as 
indicated inTable 8-2and inthe SOM.  The meal tolerance test will be conducted at time 
points defined in 
theAssessment schedule and results will be used at the end of the study  to 
calculate Matsuda Index and other insulin sensitivity  parameters (Matsuda and DeFronzo 1999).
8.5.2 Imaging
[IP_ADDRESS] DXA  Scan
Dual energy  X-ray absorptiometry  (DXA) will be used to assess changes in body  composition, 
including total fat and lean body  mass (FBM and LBM) and appendicular skeletal fat and 
muscle mass (aFBM and aLBM). DXA instruments contains a source that generates x
-rays
split into two energies to measure bone mineral mass and soft tissue from which fat and fat-
free mass (or lean body  mass) are estimated. The exam is quick (~5-6 min), precise (0.5-1%) 
and non- invasive. DXA scanners have the precision required to det ect changes in muscle mass 
as small as 5%.
Quality  assurance is an important issue in the use of DXA scans to determine body 
composition. DXA instrument manufacturer and model should remain consistent and their 
calibration should be monitored throughout the study . Use of a standardized scan acquisition 
protocol and appropriate and unchanging scan acquisition and analy sis software is essential to 
achieve consistent results. Likewise, because of variability  in interpretation of the scans, it is 
important to u tilize centralized scan anal ysis by  [CONTACT_49984].
Data collection and processing is explained in the imaging charter written by [CONTACT_740153] . DXA data need to remain blinded to investigator and patient until 
database lock.
[COMPANY_001] Confidential Page 75
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.5.3 Anthropometric measurements
Height
Body weight
Waist circumference
Hip circumference
Waist to hip ratio will be calculated at the end of the study
Body mass index (BMI) will be calculated by [CONTACT_779] (Bod y weight (kg)/ [Height (m)]2)
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 76
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.6 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the Site Operations Manual, with the Assessment schedule (Section 8.1) detailing when each 
assessment is to be performed.
Company Confidential Information
[COMPANY_001] Confidential Page 77
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
8.6.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, and vascular and neurological systems . If indicated based on medical history 
and/or sy mptoms, additional exams may  be performed.
Skin-related issues will be assessed by [CONTACT_740154].  Particular attention should be devoted to the assessment of acne at baseline 
and all follow -
up visits due to the previousl y noted increased incidence of acne in people 
treated with bimagrumab. Information for all physical examinations must be included in the 
source documentation at the study  site and will not be recorded in the CRF. Significant 
findings that are present prior to informed consent are included in the Relevant Medical 
History  CRF. Significant findings observed after informed consent signature [CONTACT_740167].
8.6.2 Vital signs
Body temperature
Blood pre ssure (BP)
Pulse rate
All readings should be recorded on the CRF.
8.6.[ADDRESS_1011419] s regardless of reported 
reproductive/menopausal status. 
Urine pregnancy  tests will be used at other visits as per the Assessment Schedule and will be 
performed inwomen of child
-bearing potential only. The result of this test must be received 
before the patient may  be dosed at the current visit.
8.6.[ADDRESS_1011420] be discussed with the sponsor.
The CRF will contain:
date and time of ECG
PR interval
QT interval
QTcF
QRS duration
RR interval
[COMPANY_001] Confidential Page 78
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
The Fri dericia QT correction formula (QTcF) should be used for clinical decisions.
As applicable, QTcF may be calculated in-house. Unless auto- calculated by [CONTACT_221988], the investigator must calculate QTcF at the Screeni ng and/or Baseline visit(s) 
(asapplicable) to assess eligibility .See the Site Operations Manual for additional details.
Original ECG tracings, appropriately signed, will be archived at stud y site.
8.6.5 Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential
(e.g., neutrophils, basophils, eosinophils, monocy tes, ly mphocy tes), erythrocy te sedimentation 
rate,  platelet count, aPTT, PT , INRwill be measured.
8.6.[ADDRESS_1011421] of approximately  12 hours. Blood chemistry 
will include: Sodium, potassium, calcium, magnesium, bicarbonate/HCO 3, chloride, 
phosphate or phosphorus , creatinine, BUN or urea, uric acid, albumin, total protein, alkaline 
phosphatase, total bilirubin, LDH, γGT, AST, ALT, amylase, lipase, CK (CK-MM, CK-MB), 
myoglobin.
If the total bilirubin concentration is increased above 1.[ADDRESS_1011422] reacting bilirubin should be differentiated.
Additional safet y labs may be performed at the Investigator’ s discretion for 
clinically /medically significant abnormalities in gly cemic control.
8.6.7 Urinaly sis
A midstream urine sample (approx. 30 mL) will be obtained, in order to avoid contamination 
with epi[INVESTIGATOR_107183], and allow proper assessments. Required assessments 
include: occult blood , pH, specific gravity , ketones, glucose , protein, bilirubin, nitrite and 
leukocy tes.
8.7 Pharmacokinetics (PK)
PK samples will be collected at the time points defined in the Assessment schedule
(Section 8.1). Follow instructions outlined in the Site Operations Manu al regarding sample 
collection, numbering, processing and shipment. See Section 8.9 regarding the potential use of 
residual samples.
In order to better define the PK profile, the timing of the PK sample collection may  be altered 
based on 
emergent data. The number of samples/blood draws and total blood volume 
collected will not exceed those stated in the protocol. 
PK samples will be obtained and evaluated in all patients.
Concentrations will be expressed in mass per volume units.  
Company Confidential Information
[COMPANY_001] Confidential Page 79
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
For standard PK abbreviations and definitions see the list provided at the beginning of this 
protocol.
The following PK parameters will be determined from the serum concentration -time data 
using the actual recorded sampling times and non-compartmental method(s) with Phoenix 
WinNonlin (Version 6.2 or higher):
On Day 1, 168 and 308: Cmax, Tmax
On Day s 84, 168, 252 , 308 and 336: Ctrough
8.[ADDRESS_1011423] subjects once between monthly  in-person counseli ng visits as defined in Table 8-3. 
Subjects will be asked to report : time of day, 
food/beverage, method of preparation, portion 
size/amount consumed and details of the item, as defined in the Site Operations Manual .
Data will be entered in the CRF as total amount of calories, protein (g/kgand % calories), fat 
(gand % calories), and carboh ydrate (g and % calories).
8.8.3 Immunogenicity
Immunogenicity  (IG) samples will be collected at the time points defined in the 
Assessment schedule and anal yzed by a [COMPANY_001] CRO .
Further details on sample collection, numbering, processing and shipment can be found in the 
SOM.
A validated bridging enzy me-linked immunosorbent assay  (ELISA) will be used for screening 
and confirmation of the presence of anti-bimagrumab antibodies in human serum. 
Confirmed immunogenicity  samples will be further characterized for presence of neutralizing 
antibodies using a validated ligand binding assay . The detailed method description to assess 
immunogenicit y of bimagrumab will be described in the bioanaly tical raw data of the study 
and in the respective Bioanal ytical Data Report (BDR).
Company Confidential Information
[COMPANY_001] Confidential Page 80
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
IG samples remaining after immunogenicity  analysis may be used for exploratory  assessment or 
other bioanaly tical purposes (e.g.,cross check between different sites). Given the exploratory nature 
of the work, the analytical method used for those assessments wil l not be validated. 
8.9 Use of residual biological samples
Residual blood and urine samples may  be used for another protocol specified endpoint.
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 81
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may notbe temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are 
also 
considered an AEirrespective if a clinical event has occurred. See Section 9. 6for an overview 
of the reporting requirements.
The occurrence of AEmust be sought by [CONTACT_105]-directive questioning of the patient at each visit 
during the study . AEs also may  be detected when they  are volunteered by  [CONTACT_740155], laboratory  test finding, or other 
assessments.
Abnormal laboratory  values or test results constitute AEs only if they  fulfill at least one of the 
following criteria:
they induce clinical signs or sy mptoms,
they are considered clinically
 significant,
they require therapy .
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_50067]. Investigators have the responsibili ty for managing the safet y of individual 
patient sand identify ing AEs. Alert ranges for liver and kidney  related events are included in 
Appendix 1and Appendix 2, respectivel y. Other laboratory  values to check are markers of 
muscle distress (CK, myoglobin) and pancreatic enzy mes (am ylase and lipase) .
AEs must be recorded on the Adverse Events CRF under the signs, symptoms or diagnosis 
associated with th em, and accompanied by  [CONTACT_6644]:
1.The severity :
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.Its relationship to the study  treatment :
Yes or
No
3.Its duration (start and end dates) or if the event is ongoing ,an outcome of not
recovered/not resolved must be reported.
4.Whether it constitutes a SAE (see Section 9.2 for definition of SAE) and which
seriousness criteria have been met.
[COMPANY_001] Confidential Page 82
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
5. Action taken regarding investigational treatment.   All AEs must be treated appropriatel y.
Treatment may  include one or mo re of the following:
no action taken (e.g. further observation only )
investigational treatment dosage increased/reduced
investigational treatment interrupted/withdrawn
concomitant medication or non- drug therap y given
hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059] (see Section 9.2 for definition of SAE)
6.Its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving,
recovered/resolved with sequelae; fat al; or unknown).
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications. This information will be included in the informed consent 
and should be discussed with the patient during the study  as needed.  Once an adverse event is 
detected, it must be followed until its resolution or until it is judged to be permanent, and 
assessment should be made at each visit (or more frequentl y, if necessary ) of any changes in 
severit y, the suspected relationship to the investigational drug, the interventions required to 
treat it, and the outcome.
The investigator must also instruct each patient to report any new AE(beyond the protocol 
observation period) that the patient, or the subject’s personal physician, believes might 
reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to [COMPANY_001].
In this study , investigators will be asked to provide additional details on selected adverse 
events of special interest such as but not limited to events of spontaneous muscle contraction 
with associated pain, diarrhea or diarrhea -like events .
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any AE(appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s) or medical conditions(s)) which meets an y one of the fol lowing criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition (an y diabetic -related complications)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the
indication under study   and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_740123] 83
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
social reasons and respi[INVESTIGATOR_37207]’s
general condition
is medically  significant, e.g. defined as an event that jeopardizes the subject or may
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medi cally  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex I V, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_105195]. 
Examples of such events are intensive treatment in an emergency  room or at hom e for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_109000] (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to [COMPANY_001] Chief Medical Office and Patient Safet y (CMO & PS) as per 
Secti on 9.2.2.
9.2.[ADDRESS_1011424] be reported to 
[COMPANY_001] within 24 hours of learning of its occurrence as described below. Any SAEs 
experienced after this period should only be reported to [COMPANY_001] 
if the investigator suspects a 
causal relationship to study  treatment.
Note: SAEs reported by [CONTACT_740156].
Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported as 
follow -up to the original epi[INVESTIGATOR_1865], regardle ss of when the event occurs. This report must be 
submitted within 24 hours of the investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new event.
Information about all SAEs (either initial or follow up information )is collected and recorded 
on the paper SAE Report Form. The investigator must assess the relationship to each specific 
component of study  treatment (if study  treatment consists of several d rugs) complete the SAE 
Report Form in English, and send the completed, signed form by [CONTACT_87109] 24 hours after 
awareness of the SAE to the local [COMPANY_001] Drug Safety  and Epi[INVESTIGATOR_18540], 
[COMPANY_001] Confidential Page 84
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
notify ing the Clinical Trial Leader. Contact [CONTACT_740157].
The original copy of the SAE Report Form and the fax confirmation sheet must be kept with 
the source documentation at the study  site. Follow -up information should be provided using a 
new paper SAE Report Form stating t hat this is a follow -up to a previousl y reported SAE.
SAEs (initial and follow -up) that are recorded electronically  in the Electronic Data Capture 
system should be entered, saved and e-signed within 24 hours of awareness of the SAE or 
changes to an existin g SAE. These data will automatically  be submitted to [COMPANY_001] Drug 
Safet y & Epi[INVESTIGATOR_275404] [ADDRESS_1011425] describe whether the event has resolved or continues, if 
and how it was treated, whether the blind was broken or not (if applicable) and whether the 
patient continued or withdrew from study  participation. Each recurrence , complicat ion, or 
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epi[INVESTIGATOR_50070]. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
Follow the detailed instructions outlined in the Site Operations Manual regarding the 
submission process for reporting SAEs to [COMPANY_001]. Note: SAEs must be reported to 
[COMPANY_001] within 24 hours of the investigator learning of its occurrence/receiving follow -up 
information.
9.[ADDRESS_1011426] safet y, a standardized process for identification, monitoring and evaluation 
of liver events has to be fo llowed.
Liver events are divided into two categories:
Liver events of special interest (AESI) which consist of elevated transaminases and/or
bilirubin (elevated liver function tests (LFTs)).
Medicall y significant liver events which are considered as seriou s adverse events (SAEs)
and which consist of marked elevations of LFTs and / or pre -specified adverse events.
Please refer to Table 15 -1-Appendix 1 for complete definitions of liver events.
[COMPANY_001] Confidential Page 85
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Follow -up of liver events
Every  liver event defined in Table 15 -1-Appendix 1should be followed up by  [CONTACT_233635], as summarized below. 
Additional details on actions required in case of liver events are outlined in Table 15 -2-Appendix 1 . 
Repeating liver chemistry tests (ALT, AST, TBL, PT, INR, ALP and γGT) to confirm
elevation within 48- 72 hours.
Repeat laboratory  test results must be reported as appropriate via an electronic data
transfer (if applicable), or entered on the appropriate unscheduled local laboratory  CRF.
If the initial elevation is confirmed, close observation of the patient will be initiated,
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to  Section 7.2 (Discontinuation of study
treatment), if appropriate
Hospi[INVESTIGATOR_740124] .
Causality  assessment of the liver event.
Thorough follow -up of the liver event should include:
Repeating liver chemistry tests two or three times weekl y. Testing should include
ALT, AST, AL P, PT , INR, and γ GT. If total bilirubin is elevated > [ADDRESS_1011427] bilirubin is required. To rule out muscular origin
of transaminase elevations, CPK should be measured along with liver chemistry  tests.
Frequency  of retesting can decrease to once a w eek or less if abnormalities stabilize
or the study  drug has been discontinued and the pat ient is asy mptomatic.
Retesting should be continued up to resolution.
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.
Obtaining a history  of concomitant drug use (including nonprescription medications
and herbal and dietary  supplement preparations), alcohol use, recreational drug use,
and special diets.
Exclusion of underly ing liver disease, as specified in Table 15-3 .
Imaging such as abdominal US, CT or MRI , as appropriate .
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.
[COMPANY_001] Confidential Page 86
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
9.[ADDRESS_1011428] safety and enhance reliability  in determining the potential for pancreatic 
events with bimagrumab, a standardized process for identification, monitoring and evaluation 
of pancreatic events should be followed ( Table 9 -1).
Table 9-1 Safety  monitoring guidance for am ylase and lipase elevations
Event Follow up monitoring
Lipase and/or am ylase < 3x ULN If asy mptomatic, follow up at discretion of investigator.
If clinical sy mptoms (e.g., abdominal pain, nausea, diarrhea)
suggest pancreatic involvement, re -check enzy mes
(amy lase, lipase) and inflammatory  markers (C -reactive
protein) and consider pancreatic imaging (i.e., CT or MRI) to
evaluate for presence of pancreatitis.
Lipase and/or am ylase ≥ 3x ULN Re-check enzy mes (am ylase, lipase) and inflammatory
markers (C -reactive protein) independent of presence of
clinical s ymptoms.
Assess subject for clinical sy mptoms.
Conduct pancreatic imaging (i.e., CT or MRI) to evaluate for
presence of pancreatitis.
Study drug interruption based on findings of additional
assessme nts and at discretion of investigator.
Medically significant pancreatic events which are considered as serious adverse events 
(SAEs) should follow the standard procedures for SAE reporting as described in
Section 9.2. Every  pancreatic event reported as an SAE should include a causalit y assessment 
of the event via exclusion of alternative causes (e.g., gallsto
nes, co -medication).
An investigation of the pancreas needs to be followed up until resolution. A gastroenterology 
consult can be included at the investigator’s discretion. All follow -up information, and the 
procedures performed, should be recorded in the appropriate CRFs.
9.[ADDRESS_1011429] be followed up by [CONTACT_233636]. Recommended follow -up assessments are listed in 
Appendix 2 .
9.6 Reporting medication errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient/subject 
or consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].
[COMPANY_001] Confidential Page 87
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
All study  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF.  Study  treatment errors are only  to be 
reported to [COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_50071].
All instances of misuse or abuse must be documented in the adverse event (AE) CRF 
irrespective of the misuse/abuse being associated with an AE/SAE. In addition, all instances 
of misuse or abuse must be reported to [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623] . As such, 
instances of misuse or abuse are also to be reported using the SAE form/CRF. Table 9-2
summarizes the reporting requirements.
Table 9
-2 Summary  of reporting requirements for medication errors
Treatment error typeDocument in Dose
Administration (DA R) CRFDocument in A E 
CRFComplete SA E 
form/CRF
Unintentional study 
treatment errorYes Only i f associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes YesYes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see Section 9.[ADDRESS_1011430] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or n ewborn complications.
The study  drug must be discontinued immediately , though the patient may stay in the study , 
ifshe wishes to do so. All assessments that are considered as a risk during pregnancy  must not 
be performed. The patient may continue all other protocol assessments. Pregnancy  must be 
recorded on the Pharmacovigilance Pregnancy  Form and reported by [CONTACT_740158][INVESTIGATOR_18540]. Pregnancy  follow -up should be 
recorded on the same form and should include an assessment of the possible relationship to 
the study  treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
9.8 Early phase safety  monitoring
The Investigator will monitor AEs in an ongoing manner and inform the Sponsor of any 
clinically  relevant observations. Any required safet y reviews will be made jointly  between 
medically  qualified personnel representing theSponsor and Investigator. Such evaluations 
may occur verbally , but the outcome andkey discussion points will be summarized in writing 
(e-mail) and made available to both Sponsor and all Investigator(s). Criteria pertaining to 
stoppi[INVESTIGATOR_10098] /treatment or adapting the study  design are presented above.
[COMPANY_001] Confidential Page 88
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
When two or more clinical site(s ) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by [CONTACT_50106]) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study in a timel y manner.
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study  [COMPANY_001] employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The monitor will visit the site to check 
the completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol and to Good Clinical Practice, the progress of enrollment, and ensure that study  drug 
is being stored, dispensed, and accounted for according to specifications. Key  study  personnel 
must be available to assist the monitor duri ng these visits.
Continuous remote monitoring of each site’s data may be performed by [CONTACT_5343]. 
Additionally , a central analy tics organization may  analyze data and identify risks & trends for 
site operational parameters, and provide reports to [COMPANY_001] Clinical Teams to assist with trial 
oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_102] (a signed copy  is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study-specific monitoring plan. No information in source documents about 
the identity  of the patients will be disclosed.
10.[ADDRESS_1011431] certif y 
that the data entered into the Electronic Case Report Forms are complete and accurat e. 
[COMPANY_001] Confidential Page 89
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
After database lock, the investigator will receive copi[INVESTIGATOR_105196].
Data not requiring a separate written record will be defined in the Site Operations Manual and 
Assessment schedule and can be recorded directly  on the CRFs. All other data captured for 
this study  will have an external originating source (either written or electronic) with the CRF 
not being considered as source.
All data should be record ed, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
10.[ADDRESS_1011432], which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
For laboratory  samples processed centrally ,the results will be sent electronically to [COMPANY_001] 
(or a designated CRO).
The imaging CRO will collect all imaging data (DXA ) from sites.The analysis 
results are then collected by [CONTACT_740159] a format accordin g 
to a [COMPANY_001] data transfer specification. The transformed output will then be sent to [COMPANY_001] 
data management for incorporation into the CSR. The imaging CRO will be responsible for 
all image data clarification forms and missing data at all sites.
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001].
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database hasbeen declared to be complete and accurate, it will be locked 
and the treatment codes will be unblinded and made available for data analy sis. Any changes 
to the database after that time can only be made by [CONTACT_740160].
DNA  samples (optional):
Company Confidential Information
[COMPANY_001] Confidential Page 90
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
10.4 Data Monitoring Committee
An independent, program- wide DMC is instituted for bimagrumab with focus on safet y.
The DMC will periodically  review the safet y information throughout the study  to monitor the 
trial’s progress for unexpectedl y large differences of tox icity between treatment groups. 
The DMC for the study  will be composed of individuals with experience and expertise in the 
management of patients with muscle wasting disea ses, and in the monitoring of randomized 
clinical trials as well as a DMC statistician. None of the DMC members will be involved in 
the operational conduct of the study  or any other bimagrumab clinical or pre-clinical study , 
except as a member of the DMC.
The mission of the DMC is to independently  review and evaluate the unbli nded safet y data 
generated during the study  as defined in this protocol. The DMC will ensure that study  
participants are not exposed to unnecessary  or unreasona ble risks and that the study is 
conducted with high scientific and ethical standards. As needed, theDMC will make
recommendations to the Sponsor on actions to be taken regarding the study , which may 
include the following:
Discontinuation of the study .
Suggested modifications to the study  protocol and/or the informed consent document.
Continuation of the study according to the protocol and the relevant amendments.
The DMC is accountable to the Sponsor for appropriate monitoring of the study  data.
Although the DMC may make recommendations to the Sponsor about changes in the conduct 
of the study , final decisions will be made by [CONTACT_5343]. Inthe case of early termination, 
consultation with Health Authorities may  be required.
Members of the DMC will not share any unblinded or semi-blinded information with anyone 
outside of the DMC. Particularl y, the Sponsor will rema in fully blinded to any results 
throughout the study  unless the DMC recommends chan ges in the conduct of the study  (for 
example, earl y termination due to negative sa fety findings).
An independent statistical reporting team not involved in the condu ct of the studies will 
prepare the information for the DMC according to the specifications from the DMC 
statistician. The main tasks may  include:
Generation of unblinded out puts for the DMC, including tables, figures, and listings, as
required.
Preparation of an y other reports requested b y the DMC during the closed session.
Review of the semi -blinded reports before sending to the DMC.
The frequency  of the DMC meetings will be determined by [CONTACT_740161]. 
Company Confidential Information
[COMPANY_001] Confidential Page 91
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
10.5 Adjudication Committee
Not required.
11 Data analy sis
The analy sis will be conducted on all patient data at the time the trial ends. Any data analysis 
carried out independently  by [CONTACT_105278].
11.1 Analysis sets
For all anal ysis sets, patients will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all patients that received any  study  drug.
The PK analy sis set will include all patients with at least one available valid (i.e.,not flagged 
for exclusion) PK concentration measurement, who received any study drug and with no 
protocol deviations that impact PK data.
The PD analy sis set will inclu de all patients with available PD data and no protocol deviations 
with relevant impact on PD data.
11.[ADDRESS_1011433] demographics and other baseline characteristics
All data for background and demographic variables will be listed by [CONTACT_352002]. Summ ary statistics will be provided by  [CONTACT_1570].
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by [CONTACT_90217].
11.3 Treatments
Data for study  drug administration (rescue medication) and concomitant therapi[INVESTIGATOR_351957].
11.4 Analysis of the primary  variable(s)
The primary  aim of the study  is to assess the effect of bimagrumab on fat mass at Week 48 of 
the treatment period. 
11.4.1 Variable(s)
The primary  efficacy  variable is the change from baseline in fat mass (kg) at Week 48.
Since the week 48 visit is the scheduled EOT visit, and since the EOT assessments are also 
performed in subjects who discontinue early  (see Section 7.2), only EOT assessments on 
subjects who completed a full treatment regimen (i.e., those who did not discontinue early) 
will be included in the primary  anal ysis.
[COMPANY_001] Confidential Page 92
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
11.4.2 Statistical model, hypothesis, an d method of analy sis
The study  design enables evaluation of efficacy  based onthe following dual criteria 
1)statistical significance (superior treatment effect, 1-sided 10% level) in fat mass; and
2)clinical relevance of the change in fat mass (estimated median treatment effect of 5% or
more). Weight loss of 5% has been shown to translate into clinical benefit in an
overweight/obese population with T2D (Franz et al 2015). Fat mass loss of a similar
magnitude to 
theweight loss is expected to translate into similar clinical benefits (such as on
glycemic control )in a similar population.
The randomization will be stratified by [CONTACT_150146]  (>=28 .0kg/m2and <=33 .0kg/m2, 
>33.1kg/m2to <=40 .0kg/m2) in order to achieve an approximate balance of BMI distribution
across the two treatment groups. The cutoff value of 33 kg/m2represents the expected median
BMI in that population (based on internal data); therefore the two randomization strata are
expected to be of si milar size. However, equal size strata will not be enforced. A minimum of
[ADDRESS_1011434] in both strata (see Section 11.7
).
The primary  endpoint will be analy zed using a mixed effects model. This model will have 
change from baseline in kg fat mass as the dependent variable, treatment arm,  time, 
time*treatment interaction as fixed effects, and a  subject level random intercept. Baseline fat 
mass and baseline BM I value may  be included in the model as covariates. Data collected from 
both randomization strata (BM I category  at randomization) will be included in the model. The 
change from baseline (absolute) in kg fat mass at Week 48 will be estimated from that model 
and will be summarized graphicall y and in tabular form. No transformation (logarithmic or 
otherwise ) of body  weight will be done for analysis.An unstructured within -subject 
covariance will be us ed.
The evaluation of efficacy is based on the following dual criteria:
1. statistical significance (superior treatment effect, 1- sided 10% level) in fat mass; and
2. clinical relevance of the change in fat mass (estimated median treatment effect of 5% or
more) at Week 48.
11.4.3 Handling of missing values/censoring/discontinuations
The primary  analysis model described above is valid under the assumption of data missing at 
random. If the dropout rate is greater than 10% in any arm, other analysis methods will be 
used to assess the sensitivity  of the results to different methods for missing data handling. 
11.4.4 Sensitivity analy ses
Other models may be used (such as pattern -mixture models) if the dropout rate is higher than 
expected, in order to assess sensitivity  of the primar y efficacy  conclusions to missing data. If 
a treatment effect in fat mass or HbA1c materializes, then it will be investigated whether this 
finding is robust under an assumption of informative drop-out; that the subjects who drop out 
would likely  not have e xperienced a treatment benefit.
[COMPANY_001] Confidential Page 93
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
11.5 Analysis of secondary  variable(s)
11.5.1 Efficacy  / Pharmacodynamics
11.5.2 Safety
Vital signs
All vital signs data will be listed by [CONTACT_1570], patient, and visit and if ranges are 
available ,abnormalities (an d relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided b y treatment and visit.
ECG evaluations
All ECG data will be listed by  [CONTACT_1570], patient and visit ; abnormalities will be flagged. 
Summary  statistics will be provided b y treatment and visit.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_1570], patient, and visit and if normal ranges are 
available ,abnormalities will be flagged. Summary  statistics will be provided by  [CONTACT_3148] a nd visit.
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 94
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_90217].
The number and percentage of patients with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_22058] t. A patient with multiple adverse events 
within a body  system is only  counted once towards the total of this body  system.
Other safety  evaluations
11.5.3 Pharmacokinetics
Bimagrumab serum concentration data will be listed by [CONTACT_3148], patient, and visit/sampling 
time point.
PK parameters will be listed by [CONTACT_1570], patient, visit/sampling time, and dose 
number.  Descriptive summary  statistics will include mean (arithmetic and geometric), SD, 
and CV (arithmetic and geometric), median, minimum, maximum and 90% CI. A geometric 
mean will not be reported if the dataset includes zero values. An exception to this is Tmax 
where median, minimum and maximum will be presented. Summary  statistics will include 
mean (arithmetic and geometric), SD, CV (arithmetic and geometric), median, minimum and 
maximum.
11.5.4 Pharmacokinetic / pharmacodynamic interactions
Graphical exploration of bimagrumab PK parameters versus fat mass will be provided. Other 
graphical exploration may  be done as appropriate.
11.5.[ADDRESS_1011435] and visit.
11.6 Analysis of exploratory  variables
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 95
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
11.7 Sample size cal culation
A sample size of 68recruited subjects (34 receiving active treatment and 34placebo) is 
selected to enable at least 48 completers, assuming a dropout rate of maximum 
30%.
A sample size of 24 completers per group (total of 48 patients) provides about 70% power 
(seeTable 11-1) to pass the criteria described above for fat mass (significant reduction at the 
1-sided 10% level (compared to placebo) and an estimated median p lacebo -adjusted reduction
of at least 5%).  Assumptions used for these calculations include a true placebo -adjusted fat
loss of 6% (standard deviation 6.5%, CBYM338X2206). The associated type I error is about
1% ( Table 11 -1).
Because weight loss interventions in overweight/obese diabetic patients result in ~ 15% lower 
magnitude of response compared to overweight/obe se non
-diabetic patients ( Franz et al 2007), 
wemade the assumption that bimagrumab could have a 6% true effect on fat loss in 
overweight and obese diabetic patients (this is about 15% lower than the 7.2% effect observed 
in overweight and obese pre -
diabetics (CBYM338X2206)).
11.8 Power for analy sis of key secondary  variables
The power to pass the criteria for HbA1c (significant reduction and an estimated median 
placebo
-adjusted reduction of at least 0.5%) is about 73%. Assumptions used for these 
calculations include a true placebo -adjusted HbA1c reduction of 0.7% (standard deviation 
1.11%, internal data). The associated t ype I error is about 6%.
11.9 Interim analy ses
Company Confidential Information
Company Confidential Information
[COMPANY_001] Confidential Page 96
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare), and with the 
ethical pri nciples laid down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_50074]/Independent Ethics Committ ee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, patient recruitment 
procedures (e.g. advertisements) and any other written information to be provided to patients. 
Prior to study  start, the investigator is required to sign a protocol signature [CONTACT_16066]/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to [COMPANY_001] monitor s, auditors, [COMPANY_001] Quality  Assurance representatives, designated 
agents of [COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinical site is requested by a regulatory  authority , the investigator must inform [COMPANY_001] 
immediately  that this request has been made.
Company Confidential Information
[COMPANY_001] Confidential Page 97
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
For multi- center trials, a Coordinating Investigator [INVESTIGATOR_442136] a reviewer and signatory  for the clinical study  report. 
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report ,
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical trial results.
[ADDRESS_1011436] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health authorities, where required, it cannot be 
implemented.
All significant protocol deviations will be rec orded and reported in the CSR.
13.[ADDRESS_1011437] be 
approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to 
implementation.
Amendments that are intended to eliminate an apparent immediate hazard to patients may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
[CONTACT_6670]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.
[COMPANY_001] Confidential Page 98
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
14 References
Albanese CV, Diessel E, Genant HK (2003) Clinical Applications of Bod y Composition 
Measurements Using DXA. Journal of Clinical Densitometry , vol. 6, no. 2, 75 –85.
Apovian CM, Aronne L J, Bessesen DH, et al (2015) Pharmacological management of obesit y: 
an endocrine Societ y clinical practice guideline. J. Clin. Endocrinol. Metab. p. 342 -
62.
Arterburn D, Sofer T, B oudreau DM, et al (2016) Long -term weight change after initiating 
second -generation antidepressants.  J Clin Med 5(4):48
DeFronzo RA, Tripathy  D, Schwenke DC, et al (2011) Pi[INVESTIGATOR_740125]. N. Engl. J. Med. p. 1104-15.
Fournier B, Murray  B, Gutzwiller S, et al 
(2012) Blockade of the activin receptor IIb activates 
functional brown adipogenesis and thermogenesis by  [CONTACT_740162]. Mol. Cell. Biol. p. 2871-9.
Franz MJ, VanWormer JJ, Crain AL , et al (2007) Weight -loss outcomes: a sy stematic review 
and meta -analysis of weight -loss clinical trials with a minimum 1- year follow -up.J Am Diet 
Assoc. 107(10):1755-67
Franz MJ, Boucher J L, Rutten -Ramos S, et al (2015) L ifestyle weight -loss in tervention 
outcomes in overweight and obese adults with ty pe 2 diabetes: A s ystematic review and meta -
analysis of randomized clinical trials. J .Acad . Nutr. Diet. p. 1447 -1463.
Goldstein DJ (1992) Beneficial health effects of modest weight loss. I nt J Obes Relat Metab 
Disord. 16(6):397-415.
Hrebícek J, Janout V, Malincíková J, et al (2002) Detection of insulin resistance b y simple 
quantitative insulin sensitivity  check index QUI CKI for epi[INVESTIGATOR_740126]. J. Clin. Endocrinol. Metab. p . 144 -7.
Knowler WC, Barrett -Connor E, Fowler SE, et al (2002) Reduction in the incidence of t ype [ADDRESS_1011438] yle intervention or metformin. N. Engl. J. Med. p. 393- 403.
Lim SS, Vos T, Flaxman AD, et al (2012) A comparative risk assessment of bur den of disease 
and injury  attributable to 67 risk factors and risk factor clusters in 21 regions, 1990- 2010: a 
systematic anal ysis for the Global Burden of Disease Study  2010. Lancet p. 2224-60.
Marena S, Montegrosso G, De Michieli F, et al (1992) Comparison of the metabolic effects of 
mixed meal and standard oral glucose tolerance test on glucose, insulin and C -peptide 
response in healthy , impaired glucose tolerance, mild and severe non -insulin -dependent 
diabetic subjects. Acta Diabetol. 29(1):29-33.
Matsuda M, DeFronzo RA (1999) Insulin sensitivity  indices obtained from oral glucose 
tolerance testing: comparison with eugl ycemic insulin clamp. Diabetes Care p. 1462 -70
Mechanick J I,Hurley  DL, Garvey  WT (2016) Adiposity -based chronic disease as a ne w 
diagnostic term: american association of clinical endocrinologists and the american college of 
endocrinology  position statement. Endocr Pract In- Press
[COMPANY_001] Confidential Page 99
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Rijkelijkhuizen JM, Girman CJ, Mari A, et al (2009) Classical and model -based estimates of 
beta-cell fu nction during a mixed meal vs. an OGTT in a population -based cohort. Diabetes 
Res. Clin. Pract. p. 280-8.
Stabin MG (2008) Radiopharmaceuticals for nuclear cardiology : radiation dosimetry , 
uncertainties, and risk. J. Nucl. Med. p. [ADDRESS_1011439], Zhao B, Yang J (2008) Enhanced muscle b y myostatin propeptide increases 
adipose tissue adiponectin, PPAR -alpha, and PPAR -gamma expressions. Biochem. Bioph ys. 
Res. Commun. p. 767 -73.
Tomlinson B, Cruickshank JM, Hay es Y, et al (1990) Selective beta -adrenocceptor partial
agonist effects of pi[INVESTIGATOR_740127] b y plasma creatinine
kinase changes in healthy  subjects. Brj J Pharmac; 30: 665 -672.
U.S. Department of Health and Human Services (2008) 2008 phy sical activity  guidelines for 
Americans. 
Van Gaal LF, Mertens IL, Ballaux D (2005) What is the relationship between risk factor 
reduction and degree of weight loss? Eur Heart J Suppl;7:L 21–L26
Vidal J (2002) 
Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord. 
[ADDRESS_1011440] 4:S25-8.
Wallace TM, Lev y JC andMatthews DR (2004) Use and abuse of HOMA modeling. Diabetes 
Care, 27, 1487–1495
Weiss EP, Fields DA, Mittendorfer B, et al (2008) Reproducibility  of postprandial lipemia 
tests and validity  of an abbreviated 4- hour test. Metab Clin Exp. 57:1479–85
World Health Organization (2015) World Health Organization obesity  and overweight fact 
sheet.
Yokoy ama H, Emoto M, Fujiwara S, et al (2004) Quantitative insulin sensitivity  check index 
and the reciprocal index of homeostasis model assessment are useful indexes of insulin 
resistance in t ype 2 diabetic patients with wide range of fasting plasma glucose. J. Clin. 
Endocrinol. Metab. p. 1481-4.
[COMPANY_001] Confidential Page 100
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
15 Appendix 1: Liver Event Definitions and Follo w-up 
Requirements
Table 15-1 Liver Event Definitions
Definition Thresholds
Potential Hy’s law cases ALT or AST > 3 × ULN and TBL > 2 × ULN without initial increase in ALP
to > 2 × ULN
ALT or AST elevation with 
coagulopathyALT or AST > 3 × ULN and INR > 1.5 (in the absence of anticoagulation)
ALT or AST elevation 
accompanied by [CONTACT_23805]ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue,
abdominal pain, nausea, or vomiting, or rash, or eosinophilia
Isolated ALT or AST elevation ALT or AST > 8 × ULN
[ADDRESS_1011441] < ALT/AST ≤[ADDRESS_1011442]
[ADDRESS_1011443] < ALT/AST ≤[ADDRESS_1011444]
Isolated ALP elevation ALP > 2 × ULN (in the absence of known bone pathology)
OthersAny clinical event of jaundice (or equivalent term)
Any adverse event potentially indicative of liver toxicity
Table 15-2 Actions required for Liver Events
Criteria Actions required
Potential Hy’s Law case
Discontinue the study treatment immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete CRFs per liver event guidanceALT or AST elevation with coagulopathy
ALT or AST elevation accompanied by 
[CONTACT_442153] > 8 × ULN
Jaundice
Isolated ALT or AST elevation > 5 to ≤ 8 × 
ULNIf confirmed, consider interruption or discontinuation of
study drug
If elevation persists for more than 2 weeks, discontinue the
study drug
Establish causality
Complete CRFs per liver event guidance
Isolated ALT or AST elevation > 3 to ≤ 5 × 
ULN (patient is asymptomatic)Monitor liver chemistry tests two or three times weekly
Isolated ALP elevation Repeat liver chemistry tests within 48 -72 hours
If elevation is confirmed, measure fractionat ed ALP; if >50%
is of liver origin, establish hepatic causality
Complete CRFs per liver event guidance
Any AE potentially indicative of liver toxicityConsider study treatment interruption or discontinuation
Hospi[INVESTIGATOR_18553]
Complete CRFs per liver event guidance
[COMPANY_001] Confidential Page 101
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Table 15-3 Exclusion of underly ing liver disease
Disease Assessment
Hepatitis A, B, C, E IgM anti -HAV; HBSAg, IgM anti -HBc, HBV DNA; anti-HCV, HCV
RNA, IgM & IgG anti -HEV, HEV RNA
CMV, HSV, EBV infection IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV
Autoimmune hepatitis ANA & ASMA titers, total IgM, IgG, IgE, IgA
Alcoholic hepatitis Ethanol history, γGT, MCV, CD -transfer rin
Nonalcoholic steatohepatitis Ultrasound or MRI
Hypoxic/ischemic hepatopathy Medical histor y: acute or chronic CHF, hypotension, hypoxia,
hepatic venous occlusion. Ultrasound or MRI.
Biliar y tract disease Ultrasound or MRI, ERCP as appropriate.
Wilson disease Caeruloplasmin
Hemochromatosis Ferritin, transferrin
Alpha -1-antitr ypsin deficiency Alpha -1-antitr ypsin
[COMPANY_001] Confidential Page 102
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
16 Appendix 2: Specific Renal A lert Criteria and A ctions
Table 16-1 Specific Renal A lert Criteria and A ctions
Criteria Action required
Serum creatinine (sCr) increase
25 –49% compared to baselineConsider causes and possible interventions
Follow up within 2 -5 day s
Serum creatinine increase > 50% Consider causes and possible interventions
Repeat assessment within 24 -48h if possible
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
Consider hospi[INVESTIGATOR_233610] -creatinine or albumin -creatinine ratio 
increase ≥ 2 -fold
or
new onset dipstick proteinuria ≥ 1+
or
Albumin -creatinine ratio (ACR) ≥ 30 mg/g or ≥ 
3 mg/mmol;
or
Protein -creatinine ratio (PCR ) ≥ 150 mg/g or 
>15 mg/mmolConsider causes and possible interventions
Assess serum albumin & serum protein
Repeat assessment to confirm
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
New onset glucosuria on urine dipstick (unless 
related to concomitant treatment, diabetes)Assess & document:
Blood glucose (fasting)
Serum creatinine
Urine albumin -creatinine ratio
New hematuria on dipstickAssess & document:
Urine sediment microscopy
Assess sCr and urine albumin- creatinine ratio
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation
Consider bleeding disorder
Additional specialized assessments are available to assess renal function or renal pathology . 
(Note: In exceptional cases when a nephrologist considers a renal biopsy , it is strongl y 
recommended to make specimen slides available for evaluation by [CONTACT_233645] y 
identify  project -wide patterns of nephrotoxicity .)
[COMPANY_001] Confidential Page 103
Amended Protocol Version v05 (Clean ) Protocol No. CBYM338X2211
Whenever a renal event is identified, a detailed patient history  and examination are indicated 
to identify , document and potentiall yeliminate risk factors that may have initiated or 
contributed to the event:
Blood pressure assessment (after [ADDRESS_1011445], with an appropriate cuff size)
Signs and s ymptoms such as fever, headache, shortness of breath, back or abdominal pain,
dysuria, hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake, voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic
failure, contrast media or other known nephrotoxin administration, or other potential
causes of renal d ysfunction, e.g., dehy dration, hemorrhage, tumor l ysis
Table 16-2 Follo w-up of renal events
Action Follow up
Assess *, document and record in the Case 
Report Form (CRF) or via electronic data load. 
Review and record possible contributing factors 
to the renal event (co -medications, other co -
morbid conditions) and additional diagnostic 
procedures (MRI etc) in the CRF.Urine dipstick and sediment microscopy
Blood pressure and body weight
Serum creatinine, electrolytes (sodium,
potassium, phosphate, calcium), bicarbonate
and uric acid
Urine output
Monitor subject regularly (frequency at 
investigator’s discretion) until:Event resolution: (sCr within 10% of baseline or
protein -creatinine ratio within 50% of baseline)
or
Event stabilization: sCr level with ±10%
variability over last 6 months or protein -
creatinine ratio stabilization at a new level with
±50% variabili ty over last 6 months.
* Urine osmolality: in the absence of diuretics or chronic kidney disease this can be a very sensitive
metric for integrated kidney function that requires excellent tubular function. A high urinar y osm olality
in the setting of an in crease in sCr will point toward a “pre -renal” cause rather than tubular toxicity.